

TEAR HERE

PLEASE FILL IN BLOCK LETTERS

Printed by : www.westernpress.in

TEAR HERE

COMMON BID CUM APPLICATION FORM



(Please scan this QR Code to view the Red Herring Prospectus, Price Band Ad and Abridged Prospectus)



SYMBIOTEC PHARMALAB LIMITED - INITIAL PUBLIC OFFER - NR

Corporate Identity Number: U24232MP2002PLC015293; Website: www.symbiotec.com
Registered and Corporate Office: 385/2, Pigdambar, Rau, Mhow, Indore - 453 331, Madhya Pradesh, India
Contact Person: Salil Jain, Company Secretary and Compliance Officer; Telephone: +91 731 667 6405;
Email: secretarial@symbiotec.com

FOR NON-RESIDENTS INCLUDING ELIGIBLE NRIs, FPIs OR FVCIs REGISTERED MULTILATERAL AND BILATERAL DEVELOPMENT FINANCIAL INSTITUTIONS APPLYING ON A REPATRIATION BASIS

To,
The Board of Directors
SYMBIOTEC PHARMALAB LIMITED

100% BOOK BUILT OFFER
ISIN: INE899101028
LEI: 335800C8X96Y9XFOZS81

Bid cum Application Form No.

MEMBERS OF THE SYNDICATE STAMP & CODE	SUB-SYNDICATE MEMBER'S/REGISTERED BROKER'S/SCSB/CDP/RTA STAMP & CODE
SUB-BROKER / SUB-AGENT STAMP & CODE	SCSB BRANCH STAMP & CODE
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.

1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER	
Mr./Ms./M/s. _____	
Address _____	
Email _____	
Tel. No. (with STD code) / Mobile _____	
2. PAN OF SOLE / FIRST BIDDER	

3. BIDDER'S DEPOSITORY ACCOUNT DETAILS	☐ NSDL ☐ CDSL

For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID

Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of Bid Lot as advertised)							Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1 only) (In Figures only)												
								Bid Price				Retail Discount				Net Price				"Cut-off" (Please ✓/tick)
Option 1																				
(OR) Option 2																				
(OR) Option 3																				

5. CATEGORY	6. INVESTOR STATUS
☐ Retail Individual Bidder	☐ Non-Resident Indian(s) (Repatriation basis) - NRI
☐ Non-Institutional Bidder	☐ Overseas Citizen of India - OCI
☐ QIB	☐ Person Resident Outside India (Repatriation basis) - PROI
	☐ Registered Bilateral and Multilateral Development Financial Institutions - RBM
	☐ Foreign Venture Capital Investor - FVCI
	☐ Foreign Portfolio Investor - FPI
	☐ All entities other than QIBs, Bodies Corporate and Individuals - NOH
	☐ Other QIBs - OTH

7. PAYMENT DETAILS [IN CAPITAL LETTERS]		PAYMENT OPTION : FULL PAYMENT ☒
Amount blocked (₹ in figures) _____ (₹ in words) _____		
ASBA		
Bank A/c No. _____		
Bank Name & Branch _____		
Bank A/c reference number _____		
OR		
UPI ID (Maximum 45 characters) _____		

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS COMMON BID CUM APPLICATION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC OFFER ("GID") AND HEREBY AGREE AND CONFIRM THE 'BIDDER'S UNDERTAKING' AS GIVEN OVERLEAF. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THIS COMMON BID CUM APPLICATION FORM GIVEN OVERLEAF.

8A. SIGNATURE OF SOLE / FIRST BIDDER

Date : _____, 2026

8B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)
I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer.
1) _____
2) _____
3) _____

8C. MEMBERS OF THE SYNDICATE / SUB-SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchanges system)



SYMBIOTEC PHARMALAB LIMITED
INITIAL PUBLIC OFFER - NR

Acknowledgement Slip for Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agents

Bid cum Application Form No.

DP ID / CL ID	_____
---------------	-------

PAN of Sole / First Bidder

Amount blocked (₹ in figures)	ASBA Bank A/c No./UPI ID
Bank Name & Branch	
Received from Mr./Ms./M/s.	
Telephone / Mobile	Email

STAMP & SIGNATURE OF SCSB BRANCH / MEMBERS OF THE SYNDICATE / SUB-SYNDICATE MEMBER / REGISTERED BROKER / CDP / RTA / AGENTS

SYMBIOTEC PHARMALAB LIMITED - INITIAL PUBLIC OFFER - NR

	Option 1	Option 2	Option 3
No. of Equity Shares			
Bid Price per Equity Share (₹)			
Amount Blocked (₹ in figures)			
ASBA Bank A/c No./UPI ID			
Bank Name & Branch			

Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agents

Name of Sole / First Bidder

Acknowledgement Slip for Bidder
Bid cum Application Form No.

Important Note : Application made using third party UPI ID or third party ASBA Bank Account are liable to be rejected.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS DATED AUGUST 18, 2026, (THE "RHP"). YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE RHP.

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID CUM APPLICATION FORM

(IN CASE OF A JOINT BID APPLICATION, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL THE JOINT BIDDERS, THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE OFFER OF EQUITY SHARES).

The Equity Shares offered in the Offer have not been and will not be registered, listed or otherwise qualified in any other jurisdiction except India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction, outside India. On the basis of the RHP, which was filed with the Registrar of Companies, Madhya Pradesh at Gwalior (the "RoC"), (if I am/we are in India), or the RHP and the preliminary international wrap dated August 18, 2026, (the "Preliminary International Wrap" and together with the RHP, the "Preliminary Offering Memorandum") (if I am/we are outside India), General Information Document for Investing in Public Offers ("GID") and having studied the attached details as per the abridged prospectus (the "Abridged Prospectus"), I/we hereby apply for Allotment to me/us of the Equity Shares in the Offer up to my/our Bids for the maximum number of Equity Shares at or above the Offer Price, to be discovered through the Book Building Process. I/we hereby confirm that I am/we are eligible person(s) to invest in the Offer in accordance with applicable laws. The amount payable on Bidding has been blocked in the ASBA Account with the relevant SCBs or the bank account linked with the UPI ID (in case of UPI Bidders using UPI Mechanism) as mentioned in this Bid cum Application Form, as the case may be. I/we hereby confirm that I/we do not require approval from any regulatory authority to invest in the Offer according to applicable laws. I/we agree to accept the Equity Shares Bid for, or such lesser number as may be Allotted to me/us subject to the terms of the RHP (if I am/we are in India), Preliminary Offering Memorandum (if I am/we are outside India), Abridged Prospectus, the GID, this Bid cum Application Form and other applicable laws. I/we undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address as given in the Depository records and to place my/our name on the register of members of the Company. I/we acknowledge that in case of QIB Bidders (for Bids other than the Bids by Anchor Investors), only (i) the SCBs (for Bids other than the Bids by Anchor Investors) and (ii) the Book Running Lead Managers (the "BRLMs" or "Book Running Lead Managers") and their respective affiliated members of the syndicate (only in the Specified Locations) have the right to reject Bids (including on technical grounds) at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas it has to reject to reject to Non-Institutional Bidders and Retail Individual Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP or the Preliminary Offering Memorandum, as applicable. I/we authorise the Company to make the necessary changes to the extent required as per SEBI Regulations, this Bid cum Application Form and the RHP for filing of Prospectus with the RoC without intimation to me/us and use this Bid cum Application Form as the application form for the purpose of the Offer. I/we confirm that I/we have read the RHP (if I am/we are in India) or the Preliminary Offering Memorandum (if I am/we are outside India) and will be provided access to the Prospectus (if I am/we are Resident in India) or the Final Offering Memorandum (if I am/we are Resident outside India). I/we confirm that my/our investment decision is solely based on my/our independent verification and external advice on, the RHP or the Preliminary Offering Memorandum, as applicable and the Prospectus or the Final Offering Memorandum, as applicable. Any investment decision should be based on independent verification and external advice.

I/WE CONFIRM THAT: I/we and any customer I/we represent, (A) am/are located outside the United States within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") and am/are purchasing the Equity Shares in an "offshore transaction" as defined in Regulation S; (B) I/we represent, warrant, acknowledge and agree with Company, the Selling Shareholders and the Members of the Syndicate as follows: EITHER I am/we are Indian national(s) resident in India and I am/we are not applying for the said Equity Shares as nominees of any person resident outside India or foreign nationals OR I am/we are Indian national(s) resident in India and I am/we are applying for the said Equity Shares as power of attorney holder(s) of non-resident Indian(s) as mentioned on non-repatriation basis OR I am/we are Indian national(s) resident outside India and I am/we are applying for the said Equity Shares on my/our own behalf through NRO account on non-repatriation basis. I/we represent, warrant, acknowledge and agree with the Company, the Selling Shareholders and the Members of the Syndicate as follows: (A) I/we have received a copy of the RHP (if I am/we are in India) or the Preliminary Offering Memorandum (if I am/we are outside India) and have read it, and that my/our investment decision is based on the RHP or the Preliminary Offering Memorandum, as applicable; (B) I/we have read and agree to the representations, warranties, acknowledgements and agreements contained in the section entitled "Offer Procedure" on page 451 of the RHP and either (1) the sections "Terms of the Offer" and "Other Regulatory and Statutory Disclosures" on page 439 and 422 of the RHP, respectively, if I/we are in India; or (2) the sections "Transfer Restrictions" and "Distribution and Solicitation Restrictions" sections of the Preliminary Offering Memorandum, if I am/we are outside India. I/we and any person I/we represent or the accounts on whose behalf I/we are purchasing the Equity Shares confirm that (A) I/we understand that the Equity Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States, and, unless so registered, may not be offered or sold within the United States or to, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws in the United States; and (B) I/we are not an affiliate of the Company or a person acting on behalf of such jurisdiction. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. We are and any person we represent or the accounts on whose behalf we are purchasing the Equity Shares (A) are outside the United States and acquiring in "offshore transactions" as defined in, and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; (B) agree to the terms and conditions in (1) this Application Form and (2) the RHP and the Prospectus, if I am/we are in India, or the Preliminary Offering Memorandum and the Final Offering Memorandum, if I am/we are outside India; (C) I am/we are purchasing the Equity Shares pursuant to the laws of the jurisdictions applicable to me/us; (D) I/we are not an affiliate of the Company or a person acting on behalf of such affiliate; (E) if I am/we are making an application to acquire any of the Equity Shares as fiduciary or agent for one or more investor accounts, I/we have sole investment discretion with respect to each such account and I/we have full power to make the foregoing representations, warranties, acknowledgements and agreements on behalf of each such account; and (F) if I/we are making an application to acquire any of the Equity Shares for one or more managed accounts, I am/we are authorized in writing by each such managed account to subscribe to the Equity Shares for each such managed account and to make (and I/we hereby make) the representations, warranties, acknowledgements and agreements herein for and on behalf of each such account, reading the reference to "I/we" to include such accounts.

FOR QIB BIDDERS: We confirm that the Bid size/maximum Equity Shares applied for by us does not exceed the relevant regulatory approvals/limits. We are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

Further: 1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and as disclosed in the RHP or the Preliminary Offering Memorandum, as applicable, I/we agree to indemnify and hold the Company, the Selling Shareholders and the Members of the Syndicate harmless from and all costs, claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any breach of these representations, warranties or agreements and I/we agree that the indemnity set forth in herein shall survive the resale of the Equity Shares purchased in the Offer. I/we authorise (a) the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centers) or the SCBs (at Designated SCBs Branches) or the RTAs (at Designated RTA Locations) or the CDPs (at Designated CDP Locations), as the case may be, to do all acts as are necessary to make the application in the Offer, including uploading my/our Bid, blocking, unblocking of funds in the bank account of the applicant maintained with the SCBS as specified in this Bid cum Application Form or in the bank account of the Applicant linked with the UPI ID provided in this Bid cum Application Form, as the case may be, transfer of funds to the Public Offer Account on receipt of instruction from Registrar to the Offer or the Sponsor Banks, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Offer or Sponsor Banks, as the case may be, to offer instruction to the SCBSs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCBS/Registrar to the Offer shall reject the application. 3) I/we hereby authorise the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centers) or the SCBs (at Designated SCBs Branches) or CDPs (at Designated CDP Locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band.

I/we hereby provide my/our consent to the Stock Exchanges / Sponsor Banks / NPCI / Registrar to the Offer for collecting, storing and usage validating my/our PAN details from the bank account where my/our amount is blocked by the relevant SCBSs.

I/we acknowledge that as per existing policy of the Government of India, OCBs cannot participate in the Offer. I am/we are not an OCB. For further details, see "Offer Procedure" and "Restrictions on Foreign Ownership of Indian Securities" beginning on pages 451 and 474 respectively, of the RHP.

INSTRUCTIONS FOR FILLING UP THIS BID CUM APPLICATION FORM

- Name of sole/first Bidder should be exactly the same as it appears in the depository records. In case of joint Bids, only the name of the first Bidder (which should also be the first name in which the beneficiary account is held) should be provided in this Bid cum Application Form. The Bid means an "indication to make an offer" during the Bid/Offer Period by a Bidder and not an offer.
- The first Bidder, should mention his/her PAN allotted under the Income Tax Act, 1961, DP ID, Client ID and UPI ID (as applicable). Except for Bids by or on behalf of the Central or State Government and the officials appointed by the courts and by investors who are exempt from the requirement of obtaining/ specifying their PAN for transacting in the securities market and by persons residing in the state of Sikkim, any other category of Bidders, including without limitation, multilateral/bilateral development financial institutions, the Bidders, or in the case of Bid in joint names, the first Bidder (the first name under which the beneficiary account is held), should mention his/her PAN allotted under the Income Tax Act, 1961. Any Bid cum Application Form without the PAN is liable to be rejected other than as specified above.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar to the Offer will obtain Demographic Details registered with Depository Participants to be used, among other things, for Allotment, technical rejections or unblocking ASBA Account. Hence, Bidders are advised to immediately update any change in their Demographic Details as appearing on the records of the Depository Participant to ensure accuracy of records. Please note that failure to do so could result in failure in Allotment of Equity Shares and delays in unblocking of ASBA Account at the Bidders' sole risk and neither the Members of the Syndicate nor the Registered Brokers nor the Registrar to the Offer nor RTAs/CDPs nor the SCBSs nor the Company nor the Selling Shareholders shall have any responsibility or undertake any liability for the same.
- Bid Lot and Price Band:** The face value of equity shares is ₹ 2 each. The price band, Employee discount and the minimum bid lot has been decided by our Company, in consultation with the BRLMs and will be advertised in all editions of Financial Express, a widely circulated English national daily newspaper, in all editions of Jansatta, a widely circulated Hindi national daily newspaper and Indore edition of Indore Samachar, a Hindi daily newspaper (Hindi also being the regional language of Madhya Pradesh, where our Company's Registered and Corporate Office is located), each with wide circulation, at least two (2) Working Days prior to the Bid/Offer Opening Date, with the relevant financial ratios calculated at the Floor Price and at the Cap Price and have been made available to the BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") and together with BSE, the "Stock Exchanges" for the purpose of uploading on their websites in accordance with SEBI ICDR Regulations. In case of revision of the Price Band, the Bid/Offer Period will be extended by at least three (3) additional Working Days after revision of Price Band subject to the Bid/Offer Period not exceeding a total of ten (10) Working Days. In case of force majeure, banking strike or similar unforeseen circumstances, the Company in consultation with the BRLMs, for reasons to be recorded in writing, may extend the Bid/Offer Period for a minimum of one (1) Working Day, subject to the Bid/Offer Period not exceeding ten (10) Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice and also by indicating the changes on the websites of the BRLMs, and at the terminals of the Members of the Syndicate and by intimation to SCBSs, other Designated Intermediaries and the Sponsor Banks as applicable.
- Maximum and Minimum Bid Size:** In case of Retail Individual Bidders, such number of Equity Shares in multiples of the minimum Bid Lot such that the Bid Amount does not exceed ₹200,000. Bids at the Cut-Off Price indicate their agreement to purchase the Equity Shares at the Offer Price, as determined at the completion of the Book Building Process. In case of Non-Institutional Bidders and QIB Bidders, the minimum Bid size shall be such number of Equity Shares in multiples of the minimum Bid Lot such that Bid Amount exceeds ₹ 200,000. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws and mentioned in the RHP or Preliminary Offering Memorandum, as applicable.
- Please tick category as applicable to ensure proper upload of Bid in Stock Exchanges system.
- Please tick investor status as applicable. Please ensure investor status is updated in your depository records.
- Cheques/Demand Draft/Cash/stock invest/money orders/postal orders will not be accepted.** Eligible NRIs bidding on a non-repatriation basis by using the Resident Bid cum Application Form are required to authorise their SCBS to confirm or accept the UPI Mandate Request (in case of UPI Bidders Bidding through the UPI Mechanism) Bidders Bidding through the UPI Mechanism) to block their Non-Resident Ordinary ("NRO") Accounts for the full Bid Amount, at the time of the submission of this Bid cum Application Form. All Bidders including the Eligible NRI Bidders Bidding on a repatriation basis by using the Non-Resident Forms should authorize their SCBS (if they are Bidding directly through the SCBS) or confirm or accept the UPI Mandate Request (in case of UPI Bidders Bidding through the UPI Mechanism) to block their Non-Resident External ("NRE") accounts, or Foreign Currency Non-Resident ("FCNR") Accounts. All Bidders including the Eligible NRIs Bidding on a non-repatriation basis can obtain this Bid cum Application Form from the Registered and Corporate Office of the Company or from any of the Members of the Syndicate or CDPs or RTAs or Registered Brokers from the Bidding Centers. In accordance with applicable law and UPI Circulars, Bidders to please ensure that SCBS where the ASBA Account is maintained has notified at least one branch in the location where Bid cum Application Forms will be deposited by Designated Intermediaries.
- Please note that application made using third party UPI ID or third party ASBA Bank Account are liable to be rejected.
 - QIBs and Non-Institutional Bidders with bids more than ₹ 500,000 cannot use UPI mechanism to apply. UPI Bidders applying up to ₹ 500,000 shall apply through UPI mode as per NPCI vide circular reference no. NPCI/UPI/OC No. 127/2021-22 dated December 09, 2021 read with SEBI Master Circular no. HO/49/14/14/2026-CFD-POD2/14518/2026 dated February 09, 2026.
 - For Retail Individual Bidders (RIBs) and Non-Institutional Bidders with Application size up to ₹500,000 ("UPI Bidders") bidding through the UPI Mechanism:**
 - Please ensure that your bank is offering UPI facility for public Offers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Bidders Bidding using the UPI Mechanism may apply through the SCBSs and mobile applications whose names appear on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpr=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpr=yes&intmid=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to ensure with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
 - UPI Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on page 451 of the RHP.
- Only the Sole Bidder/First Bidder is required to sign this Bid cum Application Form /Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the first Bidder is not the account holder, ensure that this Bid cum Application Form is signed by the account holder. Necessary revisions in the Bidders' undertaking and instructions will be required depending upon the jurisdiction in which the offer of shares is proposed.
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the members of the Syndicate, Registered Broker, CDPs, RTAs, and/or SCBSs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms; and c. Ensure that all applicable documents in support of the Bid are attached with this Bid cum Application Form.
- The Bidders may note that in case the DP ID, Client ID and PAN mentioned in this Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchanges do not match with the DP ID, Client ID and PAN available in the Depository database, this Bid cum Application Form is liable to be rejected. Investors must ensure that their PAN is linked. This is not relevant any more as there were extensions granted under law and have now expired. You may be sent the RHP and the Prospectus (if you are Resident in India) or the Preliminary Offering Memorandum and the final offering memorandum (if you are resident outside India) either in physical form or electric form or both. You shall not distribute or forward these documents and these documents are subject to the disclaimers and restrictions contained in or accompanying them.
- The Equity Shares have not been and will not be registered under the U.S. Securities Act or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where those offers and sales are made.
- This Bid Application form is being offered to you on the basis that you (i) confirm that the representations, warranties, agreements and acknowledgements set out in "Other Regulatory and Statutory Disclosures" "Terms of the Offer" and "Offer Procedure" on pages 422, 439 and 451 respectively of the RHP and (ii) agree to abide by (1) this Bid cum Application Form and (2) the RHP (if you are in India) or the Preliminary Offering Memorandum (if you are outside India) together with the terms and conditions contained therein.
- You may be sent the RHP and the Prospectus (if you are Resident in India) or the Preliminary Offering Memorandum and the final offering memorandum (if you are resident outside India) either in physical form or electric form or both. You shall not distribute or forward this document and these documents are subject to the disclaimers and restrictions contained in or accompanying them.

Notes: Terms used but not defined herein shall have the meaning assigned to such terms in the RHP or the Preliminary Offering Memorandum, as applicable. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is also available on the respective websites of the BRLMs and the Stock Exchanges.

TEAR HERE

COMPANY CONTACT DETAILS		REGISTRAR TO THE OFFER CONTACT DETAILS
SYMBIOTEC PHARMALAB LIMITED Corporate Identity Number: U24232MP2002PLC015293; Website: www.symbiotec.com Registered and Corporate Office: 385/2, Pigdamber, Rau, Mhow, Indore - 453 331, Madhya Pradesh, India Contact Person: Salil Jain, Company Secretary and Compliance Officer; Telephone: +91 731 667 6405; Email: secretarial@symbiotec.com		MUFUG INTIME INDIA PRIVATE LIMITED (Formerly Link Intime India Private Limited) C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India Telephone: +91 810 811 4949 Email: symbiotecpharmalab ipo@in.mpmf.com Investor grievance email: symbiotecpharmalab.ipo@in.mpmf.com Website: www.in.mpmf.com Contact person: Shanti Gopalkrishnan SEBI Registration No: INR000004058



SYMBIOTEC PHARMALAB LIMITED

CORPORATE IDENTITY NUMBER: U24232MP2002PLC015293

REGISTERED AND CORPORATE OFFICE	CONTACT PERSON	EMAIL AND TELEPHONE	WEBSITE
385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India	Salil Jain <i>Company Secretary and Compliance Officer</i>	Email: secretarial@symbiotec.com Telephone: +91 731 667 6405	www.symbiotec.com

THE PROMOTERS OF OUR COMPANY: ANIL SATWANI, KASHISH SATWANI, SUSHIL SATWANI AND SATWANI HOLDINGS LLP

DETAILS OF OFFER TO THE PUBLIC				
TYPE	FRESH ISSUE SIZE	OFFER FOR SALE SIZE	TOTAL OFFER SIZE	ELIGIBILITY & SHARE RESERVATION AMONG QIBs, NIBs, RIBs & ELIGIBLE EMPLOYEES
Fresh Issue and Offer for Sale	Up to [●] Equity Shares of face value of ₹2 each aggregating up to ₹1,500.00 million	Up to [●] Equity Shares of face value of ₹2 each aggregating up to ₹16,070.00 million	Up to [●] Equity Shares of face value of ₹2 each aggregating up to ₹17,570.00 million	The Offer is being made pursuant to Regulation 6(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”). For further details, see “Other Regulatory and Statutory Disclosures – Eligibility for the Offer” on page 423. For details in relation to share reservation among QIBs, NIBs, RIBs and Eligible Employees, see “Offer Structure” on page 446.

DETAILS OF THE OFFER FOR SALE BY THE SELLING SHAREHOLDERS AND WEIGHTED AVERAGE COST OF ACQUISITION PER EQUITY SHARE			
NAME OF THE SELLING SHAREHOLDERS	TYPE	MAXIMUM NUMBER OF EQUITY SHARES OFFERED / AMOUNT (₹ IN MILLION)	WEIGHTED AVERAGE COST OF ACQUISITION PER EQUITY SHARE (IN ₹)*
Satwani Holdings LLP	Promoter Selling Shareholder	Up to [●] Equity Shares of face value of ₹2 each aggregating up to ₹1,440.00 million	49.43
Rosewood Investments	Investor Selling Shareholder	Up to [●] Equity Shares of face value of ₹2 each aggregating up to ₹9,880.00 million	147.21
India Business Excellence Fund – III	Investor Selling Shareholder	Up to [●] Equity Shares of face value of ₹2 each aggregating up to ₹4,750.00 million	147.21

*As certified by M/s. A B M S & Associates, Chartered Accountants by way of their certificate dated August 18, 2026.

RISKS IN RELATION TO THE FIRST OFFER
This being the first public issue by our Company, there has been no formal market for the Equity Shares of our Company. The face value of the Equity Shares is ₹2 each. The Floor Price, Cap Price and Offer Price determined by our Company in consultation with the Book Running Lead Managers (“BRLMs”), on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process in accordance with the SEBI ICDR Regulations, as stated under “Basis for Offer Price” on page 146, should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and / or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.
GENERAL RISK
Investments in equity and equity related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to “Risk Factors” on page 28.

ISSUER'S AND SELLING SHAREHOLDERS' ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that the Red Herring Prospectus contains all information with regard to our Company and the Offer, which is material in the context of the Offer, that the information contained in the Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes the Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect. Each of the Selling Shareholders, severally and not jointly, accepts responsibility for and only confirms the statements made or confirmed by such Selling Shareholder in the Red Herring Prospectus to the extent of information specifically pertaining to itself and its respective portion of the Offered Shares in the Offer for Sale and assumes responsibility that such statements are true and correct in all material respects and are not misleading in any material respect. However, each of the Selling Shareholders, severally and not jointly, confirms that it does not assume any responsibility for any other statements, disclosures and undertakings in the Red Herring Prospectus, including without limitation, any and all of the statements and undertakings made by or in relation to our Company or its business or any other Selling Shareholder or any other person(s).

LISTING

The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE", and together with NSE, the "Stock Exchanges"). Our Company has received 'in-principle' approvals from BSE and NSE for the listing of the Equity Shares pursuant to letters each dated February 4, 2026. For the purposes of the Offer, BSE Limited is the Designated Stock Exchange.

BOOK RUNNING LEAD MANAGERS

NAME OF BRLMs AND LOGO	CONTACT PERSON	E-MAIL AND TELEPHONE
JM Financial Limited 	Prachee Dhuri	Email: symbiotec.ipo@jmfll.com Telephone: +91 22 6630 3030
Avendus Capital Private Limited 	Sarthak Sawa / Ananya Chawla	Email: symbiotec.ipo@avendus.com Telephone: + 91 22 6648 0050
Motilal Oswal Investment Advisors Limited^{^^} 	Kunal Thakkar / Vaibhav Shah	Email: spl.ipo@motilaloswal.com Telephone: +91 22 7193 4380
Nomura Financial Advisory and Securities (India) Private Limited 	Vishal Kanjani / Chirag Shah	Email: symbiotecipo@nomura.com Telephone: +91 22 4037 4037

REGISTRAR TO THE OFFER

NAME OF REGISTRAR	CONTACT PERSON	E-MAIL AND TELEPHONE
MUFG Intime India Private Limited <i>(Formerly Link Intime India Private Limited)</i>	Shanti Gopalkrishnan	Email: symbiotecpharmalab.ipo@in.mpms.mufg.com Telephone: +91 810 811 4949

BID / OFFER PROGRAMME

ANCHOR INVESTOR BIDDING DATE	Friday, August 21, 2026 ^{**}	BID / OFFER OPENS ON	Monday, August 24, 2026	BID / OFFER CLOSING ON	Thursday, August 27, 2026 ^{***}
------------------------------	---------------------------------------	----------------------	-------------------------	------------------------	--

^{**} The Anchor Investor Bidding Date shall be one Working Day prior to the Bid / Offer Opening Date.

^{***} Our Company, in consultation with the BRLMs, may consider closing the Bid / Offer Period for QIBs one Working Day prior to the Bid / Offer Closing Date in accordance with the SEBI ICDR Regulations.

[†] The UPI mandate end time and date shall be at 5:00 p.m. on Bid / Offer Closing Date.

^{^^} In compliance with the proviso to regulation 21A(1) and explanation (iii) to regulation 21A(1) of the SEBI Merchant Bankers Regulations, and regulation 23(3) of the SEBI ICDR Regulations, Motilal Oswal Investment Advisors Limited will be involved only in marketing the Offer. Motilal Oswal Investment Advisors Limited has signed the due diligence certificate and has been disclosed as a BRLM for the Offer.



Please scan this QR code to view the Red Herring Prospectus and the Abridged Prospectus

This memorandum (the “Abridged Prospectus”) is an abridged prospectus containing salient features of the red herring prospectus dated August 18, 2026 of Symbiotec Pharmed Limited (the “Company”) filed with the Registrar of Companies, Madhya Pradesh at Gwalior (“RHP” or “Red Herring Prospectus”).

The following is a general summary of certain disclosures in the Red Herring Prospectus and the terms of the Offer and is not exhaustive, nor does it purport to contain a summary of all the disclosures in the Red Herring Prospectus or all details relevant to prospective investors. This summary should be read in conjunction with, and is qualified in its entirety by, the more detailed information appearing elsewhere in the Red Herring Prospectus, which is available at the websites of SEBI at www.sebi.gov.in, National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively, the Company at <http://investor.symbiotec.com/> and the BRLMs at www.jmfl.com, www.avendus.com, www.motilaloswal.com and www.nomuraholdings.com/company/group/asia/india/index.html. Potential investors should not rely on this Abridged Prospectus and should refer to the Red Herring Prospectus in making any investment decision.

References below to page numbers are to page numbers of the Red Herring Prospectus dated August 18, 2026. Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to them in the Red Herring Prospectus.

1. Summary of the primary business

a. Business Overview - Products and Services

We are a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms - organic chemistry, biotechnology and complex injectables. We have leveraged our deep capabilities across organic chemistry, biotechnology, and complex injectables to operate as a contract development and manufacturing organisation variably for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms in which we also manufacture our own products. Set forth below is the shareholding of our Company in our Subsidiaries as of the date of the Red Herring Prospectus:

S. No.	Name of the Subsidiary	Percentage of the issued and paid-up share capital held by our Company (%)
Direct Subsidiaries		
1.	Navisci Pte. Ltd.	100.00
2.	Knovea Pharmaceutical Private Limited	99.99 [#]
3.	Symbiotec Zenfold Private Limited	99.99 [#]
4.	Xinjiang Symbiotec Biotechnology Limited	100.00
5.	Symbiotec Biologics Private Limited	99.99 [#]
Step-down Subsidiary		
1.	Xenamed, Corp.	100.00*

[#]0.01% shareholding is held by Anil Satwani, our Promoter, as a nominee on behalf of our Company.

*Navisci Pte. Ltd., our direct Subsidiary, holds 100.00% of the issued and paid-up share capital of Xenamed, Corp.

b. Industries Served and Typical Customers

We primarily operate in the active pharmaceutical ingredient industry. Our customer portfolio comprises key generic and specialty pharmaceutical companies in major global markets such as the United States, Europe, and Asia, including several pharmaceutical majors and formulations companies. As of March 31, 2026, we had over 50 domestic customers and over 150 export customers.

c. Segment Reporting and Revenue Contribution

Our Company has only one reportable segment, i.e., manufacturing of active pharmaceutical ingredients and intermediaries.

d. Key Geographies

As of March 31, 2026, we served over 200 customers across more than 40 countries. The table below sets forth revenues generated from various geographies as per Ind AS 108 – “Operating Segments” as well as their percentage of revenue from operations in the corresponding years:

Particulars	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (₹ million)	Percentage of revenue from operations (%)	Amount (₹ million)	Percentage of revenue from operations (%)	Amount (₹ million)	Percentage of revenue from operations (%)
Revenue from external customers - India (A)	2,865.05	32.96%	3,367.75	44.81%	2,867.23	40.03%
Revenue from external customers outside India (B)	5,826.44	67.04%	4,147.79	55.19%	4,295.24	59.97%
- Europe	2,529.86	29.11%	2,271.07	30.22%	2,124.20	29.66%
- United States	1,140.00	13.12%	302.02	4.02%	642.60	8.97%
- China	82.90	0.95%	115.58	1.54%	22.19	0.31%
- Rest of the world *	2,073.68	23.86%	1,459.13	19.41%	1,506.25	21.03%
Revenue from operations (A+B)	8,691.49	100.00%	7,515.54	100.00%	7,162.47	100.00%

*Rest of the world includes Asia (other than India and China) and Africa.

e. Revenue Concentration Among Top 5 Customers

The table below sets forth the breakdown of amounts generated from our significant customers, including their percentage of sale of products, in the corresponding years:

Particulars	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (₹ million)	Percentage of revenue from sale of products (%)	Amount (₹ million)	Percentage of revenue from sale of products (%)	Amount (₹ million)	Percentage of revenue from sale of products (%)
Top five customers	3,475.98	43.01%	3,037.13	42.27%	3,154.83	48.51%

Note: The customers comprising our top five customers varied across each period.

f. Key Manufacturing Facilities

As of March 31, 2026, we had two operational industrial-scale API manufacturing facilities in Madhya Pradesh – (i) a facility at Rau, Indore, with 92 MT maximum chemical synthesis capacity; (ii) a facility at Pithampur, SEZ, with 300 KL maximum fermentation capacity and 492.67 MT maximum chemical synthesis capacity. In addition, we have commissioned a 400 KL biomanufacturing facility in Ujjain, Madhya Pradesh and a complex injectables facility at Mhow, Indore. We are also in the process of expanding our biologics capacity by adding a proposed dedicated facility for biologics manufacturing in Ujjain, Madhya Pradesh.

g. Business Strengths and Strategies

Strengths

1. Global leadership in corticosteroid and steroidal-hormone APIs;
2. Long-standing relationships with domestic and global customer base;
3. Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record;

4. Continuous investment in R&D, with leading technological capabilities among Indian peers;
5. Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings;
6. Robust financials with strong gross margins, high capital efficiency and cash conversion; and
7. Seasoned leadership team supported by strong pool of experienced management and marquee investors.

Strategies

1. Build on our global leadership by expanding our product portfolio across steroidal-hormones in our own API and ingredients business;
2. Build on fermentation capabilities and expand biotechnology offerings such as GLP-1 and Insulin;
3. Commercialize complex injectables through differentiated drug device combinations;
4. Scale up our diverse CDMO offerings based on our three interlinked differentiated platform technologies;
5. Continue to invest in new technologies, R&D for optimising products, building on historical innovation ethos; and
6. Partner with large companies for difficult-to-execute projects.

For further information, see “Our Business” beginning on page 218 of the Red Herring Prospectus.

2. Summary of the Industry (Source: F&S Report)

The global pharmaceutical market is expected to grow at a CAGR of 6.4% between 2025 and 2030, surpassing the 6.0% growth recorded from 2020 to 2025, and reaching USD 2.2 trillion by 2030, up from USD 1.2 trillion in 2020. The global API market is expanding as rising demand for generics and increasing prevalence of chronic diseases drive volume, while complex, specialty, high-value molecules boost market value. The global API market reached approximately USD 305.5 billion in 2025 and is expected to grow at a 6.8% CAGR, reaching USD 424.6 billion by 2030. The classical fermentation API market was valued at USD 491.9 million in 2025 and is expected to grow at a CAGR of 1.5% to 4.0% between 2025 and 2030. The corticosteroid API market was valued at USD 421.2 million in 2025, and it is estimated to grow at a moderate CAGR of 1.6 to 3.0% between 2025 and 2030F. Further, CDMOs play a vital role in the pharmaceutical and biotechnology industries. The CDMO market is projected to grow at an 8.2% CAGR from 2025 to 2030F, reaching USD 206.0 billion by 2030F, up from USD 139.2 billion in 2025.

For further information, see “Industry Overview” beginning on page 169 of the Red Herring Prospectus.

3. Promoters

The Promoters of our Company are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.

Anil Satwani

Anil Satwani is one of the Promoters and also the Chairman and Managing Director on the Board of our Company. He has been associated with our Company since its incorporation, i.e. September 20, 2002. He holds a bachelor’s degree in science from the Holkar Science College, Devi Ahilya Vishwavidyalaya, Indore, a master’s of arts degree in economics from the Indore Christian College, Devi Ahilya Vishwavidyalaya, Indore and a master’s degree in business administration from the Institute of Management Studies, Devi Ahilya Vishwavidyalaya, Indore. He has over 30 years of experience in the pharmaceutical sector.

Kashish Satwani

Kashish Satwani is the president of the human resources department and one of the Promoters of our Company. She has been associated with our Company since September 20, 2002. She holds a bachelor’s degree in science from Holkar Science Autonomous College, Devi Ahilya Vishwavidyalaya, Indore, a bachelor’s degree in education from Christian Aminent Academy, Devi Ahilya Vishwavidyalaya, Indore and a master’s degree in economics from the Government Girls College, Indore, Devi Ahilya Vishwavidyalaya, Indore. She has over 23 years of experience in the pharmaceutical sector.

Sushil Satwani

Sushil Satwani* is a director in the commercial department and one of the Promoters of our Company. He has been associated with our Company since September 20, 2002 and accordingly has an experience of over 23 years in the pharmaceutical sector. He holds a bachelor’s degree in commerce from Indore Christian College, Devi Ahilya Vishwavidyalaya, Indore and a master’s degree in business administration from Devi Ahilya Vishwavidyalaya, Indore.

* Sushil Satwani is not a director on our Board.

Satwani Holdings LLP

Satwani Holdings LLP was originally incorporated as Symbiotec Steroids Private Limited under the Companies Act, 1956, on September 18, 1997. Symbiotec Steroids Private Limited was converted to a limited liability partnership pursuant to limited liability partnership agreement dated March 30, 2016. Consequently, the name of Symbiotec Steroids Private Limited was changed to Symbiotec Steroids LLP. Thereafter, the name of Symbiotec Steroids LLP was changed to Satwani Holdings LLP and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 5, 2018. It is engaged in financing, investment and real estate activities.

For further information, see “Our Management” and “Our Promoters and Promoter Group” beginning on pages 276 and 301, respectively, of the Red Herring Prospectus.

4. Objects of the Offer

The Offer comprises of a Fresh Issue of up to [●] Equity Shares of face value of ₹2 each, aggregating up to ₹1,500.00 million by our Company and an Offer for Sale of up to [●] Equity Shares of face value of ₹2 each, aggregating up to ₹16,070.00 million by the Selling Shareholders.*

*Subject to finalization of Basis of Allotment

Our Company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:

S. No.	Particulars	Estimated amount (in ₹ million)
1.	Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company As at March 31, 2026, our total fund-based outstanding borrowings (on a standalone basis) amounted to ₹3,497.81 million. We propose to utilize an estimated amount of up to ₹1,125.00 million from the Net Proceeds towards pre-payment and/or repayment of all, or a portion, of certain outstanding borrowings availed by us and the interest accrued thereon.	1,125.00
2.	General corporate purposes We propose to utilize up to ₹[●] million of the balance Net Proceeds towards general corporate purposes and our business requirements as approved by the Board, from time to time, subject to such utilization for general corporate purposes not exceeding 25% of the Gross Proceeds, in compliance with the SEBI ICDR Regulations.	[●]

The respective portion of the proceeds from the Offer for Sale shall be received by each of the Selling Shareholders, after deducting their respective portion of the Offer related expenses and relevant taxes thereon, as applicable. Our Company will not receive any proceeds from the Offer for Sale by the Selling Shareholders and the proceeds from the Offer for Sale will not form part of the Net Proceeds.

For further information, see “Objects of the Offer” beginning on page 138 of the Red Herring Prospectus.

5. Pre-Offer shareholding as on the date of the Red Herring Prospectus and post-Offer shareholding as at Allotment of our Promoters, members of the Promoter Group and additional top 10 Shareholders

The aggregate pre-Offer shareholding as on the date of the Red Herring Prospectus and post-Offer shareholding as at Allotment of our Promoters, the members of our Promoter Group (other than our Promoters), additional top 10 Shareholders and other public shareholders, as a percentage of the pre-Offer and post-Offer paid-up Equity Share capital of our Company is set out below:

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

S. No.	Name of Shareholder	Pre-Offer shareholding as on the date of the Red Herring Prospectus		Post-Offer shareholding as at Allotment ^{**}			
		Number of Equity Shares of face value of ₹2 each	% of total pre-Offer paid up Equity Share capital on a fully diluted basis ^s	At the lower end of the Price Band (₹ ●)	% of the total post-Offer paid-up Equity Share capital on a fully diluted basis [@]	At the upper end of the Price Band (₹ ●)	% of the total post-Offer paid-up Equity Share capital on a fully diluted basis [@]
Promoters							
1.	Anil Satwani	2,810,896	4.48	●	●	●	●
2.	Kashish Satwani	2,750,896	4.38	●	●	●	●
3.	Sushil Satwani	1,233,938	1.97	●	●	●	●
4.	Satwani Holdings LLP*	11,277,374	17.97	●	●	●	●
Sub-total (A)		18,073,104	28.80	●	●	●	●
Promoter Group (other than our Promoters)							
1.	Kashish and Anil Satwani Family Trust	350,000	0.56	●	●	●	●
2.	Arjun Anil Satwani Family Trust	2,199,104	3.50	●	●	●	●
3.	Krishna Anil Satwani Family Trust	2,199,104	3.50	●	●	●	●
4.	Sunil Satwani	10,000	0.02	●	●	●	●
5.	Swati Sachdev	10,000	0.02	●	●	●	●
Sub-total (B)		4,748,208	7.59	●	●	●	●
Additional top 10 Shareholders							
1.	Rosewood Investments	21,825,492	34.78	●	●	●	●
2.	India Business Excellence Fund – III	15,160,906	24.16	●	●	●	●
3.	Prakash Sawlani	575,553	0.92	●	●	●	●
4.	Motilal Oswal India Excellence Fund – Mid to Mega Series III	505,000	0.80	●			
5.	Mahendra Fulchand Sundesha	329,133	0.52	●	●	●	●
6.	Goldfin Capital LLP	239,250	0.38	●	●	●	●
7.	Narnarayan Nathmal Saraf jointly with Indra Saraf	179,850	0.29	●	●	●	●
8.	Raghavender Ramachandran	75,800	0.12	●	●	●	●
9.	Raman Prasad	57,865	0.09	●	●	●	●
10.	Shubham Saboo	48,935	0.08	●	●	●	●
Sub-total (C)		38,997,784	61.14	●	●	●	●
Other public shareholders							
1.	-**	895,755	1.43	●	●	●	●
Sub-total (D)		895,755	1.43	●	●	●	●
Total (A + B + C + D)		62,734,851	100.00 ^{***}	●	●	●	●

^{*}Also, a Promoter Selling Shareholder.

[#]To be updated in the Prospectus prior to filing with the RoC.

[§]To be updated based on the Offer Price and subject to finalization of the Basis of Allotment.

[§] The percentage of the Equity Share capital on a fully diluted basis has been calculated assuming the exercise of all vested options as on the date under the ESOP Scheme.

[§] The percentage of the Equity Share capital on a fully diluted basis will be calculated assuming the exercise of all vested options under the ESOP Scheme as on the date of the Prospectus and considering any transfers of Equity Shares by existing shareholders after the date of the pre-issue and Price Band advertisement until date of Prospectus.

^{**}As on the date of the Red Herring Prospectus, our Company has 84 public shareholders.

^{***}Includes 24,570 ESOP options that have been vested but have not been exercised under the ESOP Scheme.

For further details, see “Capital Structure” beginning on page 106 of the Red Herring Prospectus.

6. Summary of Restated Consolidated Summary Statements

The following details are derived from the Restated Consolidated Summary Statements:

Particulars	As at March 31, 2026	As at March 31, 2025	As at March 31, 2024
Equity Share capital (in ₹ million)	125.47	109.36	109.36
Revenue from operations (in ₹ million) ⁽¹⁾	8,691.49 [†]	7,515.54	7,162.47
EBITDA (in ₹ million) ⁽²⁾	2,319.73	2,061.12	1,770.41
Profit after tax (in ₹ million)	1,099.03	967.85	1,000.55
Earnings per Equity Share (basic) (in ₹) ⁽³⁾	19.10	17.39	18.00
Earnings per Equity Share (diluted) (in ₹) ⁽⁴⁾	19.00	17.36	18.00
Net Worth (in ₹ million) ⁽⁵⁾	11,586.41	8,211.52	7,206.76
Return on Net Worth (in %) ⁽⁶⁾	9.48%	11.79%	13.90%
Net Asset Value per Equity Share (in ₹) ⁽⁷⁾	184.69	150.17	131.79
Total borrowings (in ₹ million)	3,879.14	5,409.23	2,472.07
Net cash flow from operating activities (in ₹ million) ⁽⁸⁾	1,745.93	472.56	1,875.02
Net cash flow used in investing activities (in ₹ million)	(2,269.30)	(3,065.24)	(2,064.06)
Net cash flow generated from / (used in) financing activities (in ₹ million)	359.87	2,781.63	218.48

[†]The revenue from operations for Fiscal 2026 included injectable revenue of ₹330.50 million.

Notes:

1. Revenue from operations means the revenue from operations for the year.

2. EBITDA is calculated as profit/(loss) for the year then adjusted other items like total income tax expense, finance cost and depreciation and amortization.

3. Earnings per share (basic) (in ₹) is calculated as profit for the year attributable to owners of the parent company divided by the weighted average number of Equity Shares outstanding during the year. Earnings per share has been computed as per Ind AS 33 – “Earnings per Share”.

4. Earnings per share (diluted) (in ₹) is calculated as profit for the year attributable to owners of the parent company divided by the weighted average number of Equity Shares outstanding during the year plus the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Earnings per share has been computed as per Ind AS 33 – “Earnings per Share”.

5. Net Worth means the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation in accordance with Regulation 2(1)(hh) of the SEBI ICDR Regulations. Net Worth is calculated by aggregate value of equity share capital and other equity excluding foreign currency translation reserve.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

6. Return on Net Worth is calculated as profit for the year attributable to owners of the parent company divided by the Net Worth as at the end of the respective year.
7. Net Asset Value per share is Net Worth as at year divided by the number of Equity Shares outstanding as at the end of the year.
8. Net cash flow from operating activities is net cash flow from operating activities for the year.

For further details, see “Restated Consolidated Summary Statements” and “Other Financial Information” beginning on pages 309 and 366, respectively, of the Red Herring Prospectus.

7. Summary of Key Performance Indicators

Details of the key performance indicators as at and for Fiscal 2026, Fiscal 2025 and Fiscal 2024, are set forth below:

(in ₹ million, unless otherwise indicated)

Particulars	Unit	Fiscal 2026	Fiscal 2025	Fiscal 2024
Revenue from operations ⁽¹⁾	INR million	8,691.49*	7,515.54	7,162.47
Revenue from operations growth ⁽²⁾	%	15.65%	4.93% **	26.43% **
API revenue ⁽³⁾	INR million	8,350.05	7,447.54	7,162.47
CDMO revenue ⁽⁴⁾	INR million	10.94	68.00	-
EBITDA ⁽⁵⁾	INR million	2,319.73	2,061.12	1,770.41
EBITDA Margin ⁽⁶⁾	%	26.59%	27.26%	24.48%
Profit after Tax ⁽⁷⁾	INR million	1,099.03	967.85	1,000.55
PAT Margin (%) ⁽⁸⁾	%	12.60%	12.80%	13.83%
PAT Growth ⁽⁹⁾	%	13.55%	-3.27%	326.02%
Earnings per share (Basic) ⁽¹⁰⁾	INR	19.10	17.39	18.00
Earnings per share (Diluted) ⁽¹¹⁾	INR	19.00	17.36	18.00
Total assets ⁽¹²⁾	INR million	17,807.92	15,796.51	12,947.85
Net Debt ⁽¹³⁾	INR million	3,808.65	5,179.73	2,430.35
Net debt/ EBITDA (times) ⁽¹⁴⁾	times	1.64	2.51	1.37
Net Worth ⁽¹⁵⁾	INR million	11,586.41	8,211.52	7,206.76
Capital Expenditure ⁽¹⁶⁾	INR million	2,373.05	3,928.96	1,766.64
Return on equity (%) ⁽¹⁷⁾	%	11.19%	12.66%	14.98%
Net Asset Value per share ⁽¹⁸⁾	INR	184.69	150.17	131.79
Return on Capital Employed (ROCE) ⁽¹⁹⁾	%	11.56%	11.80%	14.03%
Adjusted ROCE ⁽²⁰⁾	%	30.43%	27.71%	24.59%
Gross fixed assets turnover ratio ⁽²¹⁾	times	1.54	1.39	1.42
Operating Working Capital ⁽²²⁾	INR million	2,750.50	2,867.83	2,056.58
Net cash flow from operating activities ⁽²³⁾	INR million	1,745.93	472.56	1,875.02
Net cash flow from operating activities/ EBITDA (times) ⁽²⁴⁾	times	0.75	0.23	1.06
Number of API DMFs	#	66.00	64.00	64.00
Fermentation Capacity	KL	700.00***	300.00	300.00

As certified by M/s. A B M S & Associates, Chartered Accountants by way of their certificate dated August 18, 2026.

* The revenue from operations for Fiscal 2026 includes injectable revenue of ₹330.50 million

** The revenue from operations for Fiscal 2024 includes milestone revenue of ₹442.11 million, whereas the corresponding amount is Nil for Fiscal 2025. After excluding the impact of milestone revenue in Fiscal 2024, the revenue from operations growth is 11.83% for Fiscal 2025 and 18.63% for Fiscal 2024.

*** Including the commissioned manufacturing facilities of certain Subsidiaries of our Company viz. the Ujjain Facility and Mhow Facility.

Notes:

1. Revenue from operations means the revenue from operations for the year.
2. Revenue from operations growth is calculated as the percentage change in Revenue from operations as compared to the immediately preceding year.
3. API Revenue represents revenue from sales of active pharmaceutical ingredients and related intermediates.
4. CDMO revenue represents revenue from contract development and manufacturing operations for the respective year.
5. EBITDA is calculated as profit/(loss) for the year then adjusted other items like total income tax expense, finance cost and depreciation and amortization.
6. EBITDA margin is calculated as EBITDA divided by total income.
7. Profit after Tax represents net profit attributable to equity shareholders after taking into account tax expense for the year.
8. PAT Margin is calculated as profit after tax for the year divided by total income.
9. PAT Growth is calculated as the percentage change in profit after tax as compared to the immediately preceding year.
10. Earnings per share (basic) (in ₹) is calculated as profit for the year attributable to owners of the parent company divided by the weighted average number of Equity Shares outstanding during the year. Earnings per share has been computed as per Ind AS 33 – “Earnings per Share”.
11. Earnings per share (diluted) (in ₹) is calculated as profit for the year attributable to owners of the parent company divided by the weighted average number of Equity Shares outstanding during the year plus the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Earnings per share has been computed as per Ind AS 33 – “Earnings per Share”.
12. Total assets means the total assets for the year.
13. Net Debt is calculated as the sum of total borrowings and total lease liabilities less cash and cash equivalents and term deposit.
14. Net debt/ EBITDA is calculated as net debt divided by EBITDA.
15. Net Worth means the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation in accordance with Regulation 2(1)(hh) of the SEBI ICDR Regulations. Net worth is calculated by aggregate value of equity share capital and other equity excluding Foreign currency translation reserve.
16. Capital expenditure comprises additions to property, plant and equipment, capital work-in-progress, right-of-use assets and intangible assets during the respective year.
17. Return on equity is calculated as Profit/ (Loss) for the year divided by the average total equity at the end of the respective year.
18. Net Asset Value per share is calculated as Net Worth as at year divided by the number of Equity Shares outstanding as at the end of the year.
19. Return on Capital Employed (ROCE) is calculated as a percentage of earnings before interest and taxes / total equity plus total borrowings, total lease liabilities plus deferred tax liabilities minus deferred tax assets. EBIT is calculated as profit before tax and share of profit of joint ventures / associate plus finance costs.
20. Adjusted ROCE is calculated based on the consolidated average capital employed for the Fiscal after excluding the capital employed attributable to Knovea Pharmaceutical Private Limited and Symbiotec Zenfold Private Limited. Similarly, EBIT for the Fiscal is adjusted by excluding the profit / (loss) of Knovea Pharmaceutical Private Limited and Symbiotec Zenfold Private Limited to arrive at a normalised operating performance measure. These figures have been excluded because Knovea Pharmaceutical Private Limited and Symbiotec Zenfold Private Limited are not fully commercialized yet and thus is expected to generate return on capital employed in coming years.
21. Gross fixed assets turnover ratio is calculated as Revenue from operations divided by gross property, plant and equipment, capital work-in-progress, intangible assets, intangible assets under development and right-of-use assets.
22. Operating Working Capital is calculated as operating current assets less operating current liabilities, less cash and cash equivalents, short-term borrowings, lease liabilities and provisions.
23. Net cash flow from operating activities is Net cash flow from operating activities for the year.

24. *Net cash flow from operating activities/ EBITDA is calculated as Net cash flow from operating activities divided by EBITDA.*

For details of our other operating metrics disclosed elsewhere in the Red Herring Prospectus, see “Our Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” beginning on pages 218 and 371, respectively, of the Red Herring Prospectus. For further detailed disclosure on our key performance indicators, see “Basis for Offer Price” on page 146 of the Red Herring Prospectus.

8. Risk Factors

The following are the top 10 internal risk factors as disclosed in the Red Herring Prospectus:

1. We derive almost all of our revenue from the sale of APIs, which collectively constituted 96.07%, 99.10% and 100.00% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Further, our top five APIs constituted 67.27%, 63.16% and 60.37% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for APIs, and our top products in particular, or disruption in production, could have an adverse effect on our business, results of operations, financial condition and cash flows.
2. Our manufacturing facilities are subject to periodic inspections and audits by regulatory authorities and our customers. Any manufacturing or quality control failures may subject us to regulatory action, damage our reputation and have an adverse effect on our business, results of operations, financial condition and cash flows.
3. We export our products to various countries and our revenue from external customers outside India as per Ind AS 108 – “Operating Segments” represented 67.04%, 55.19% and 59.97% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Our inability to handle risks associated with our export sales could adversely affect our sales to customers in foreign countries, our results of operations, financial condition and cash flows.
4. In Fiscals 2026, 2025 and 2024, revenue from the United States represented 13.12%, 4.02% and 8.97% of our revenue from operations. The imposition of tariffs or other anti-outsourcing legislation by the United States could adversely affect our results of operations, financial condition and cash flows.
5. We derive a substantial portion of our revenue from certain key customers. Revenue generated from our top ten customers accounted for 57.59%, 55.90% and 61.65% of our revenue from sale of product in Fiscals 2026, 2025 and 2024, respectively. Loss of our relationship with any of these customers or delays or reductions in their orders could have an adverse effect on our business, results of operations, financial condition and cash flows.
6. Our manufacturing facilities and dedicated R&D centres are located in the state of Madhya Pradesh in India. Any adverse developments affecting Madhya Pradesh or its surrounding regions could adversely affect our business, results of operations, financial condition and cash flows. A slowdown, interruption or shutdown in our manufacturing operations could have an adverse effect on our business, results of operations, financial condition and cash flows.
7. We depend on certain suppliers for raw materials for our operations. Purchases from our top ten suppliers accounted for 25.50%, 18.41% and 50.33% of our total expenses in Fiscals 2026, 2025 and 2024, respectively. Any loss of such suppliers or non-performance of their obligations could adversely affect our business, results of operations, financial condition and cash flows.
8. We operate in a highly competitive market. We face competition both within our API manufacturing business and in our role as a CDMO, which we have recently commenced. An inability to compete effectively may adversely affect our business, results of operations, financial condition and cash flows.
9. We procure a portion of our raw material requirements from different countries, including China and the United States. Any adverse developments in these countries, or the laws governing our imports from these countries, could disrupt our raw material supply and adversely affect our results of operations, financial condition and cash flows.
10. Our success depends on our ability to develop and commercialise new products in a timely manner. If our research and development efforts do not succeed, or the products we commercialise do not perform as expected, the introduction of new products may be hindered, which could adversely affect our business, results of operations, financial condition and cash flows.

For further details of the risks applicable to us, see “Risk Factors” beginning on page 28 of the Red Herring Prospectus. Investors are advised to read the risk factors carefully before making an investment decision in the Offer.

9. Weighted average cost of acquisition at which Equity Shares were acquired by the Promoters (which includes the Promoter Selling Shareholder) and Selling Shareholders as on date of the Red Herring Prospectus and in the one year preceding the date of the Red Herring Prospectus

The weighted average cost of acquisition at which the Equity Shares were acquired by our Promoters and Selling Shareholders, as on date of the Red Herring Prospectus and one year preceding the date of the Red Herring Prospectus, is as follows:

S. No.	Name	Number of Equity Shares of face value of ₹ 2 each held as on date	WACA per Equity Share (in ₹)	Number of Equity Shares of face value of ₹ 2 each acquired in last one year	WACA of Equity Shares acquired in last one year
Promoters					
1.	Anil Satwani	2,810,896	276.00	3,120,000	276.00
2.	Kashish Satwani	2,750,896	273.04	2,700,000	276.00
3.	Sushil Satwani	1,233,938	72.37	313,938	276.00
4.	Satwani Holdings LLP [*]	11,277,374	49.43	2,227,734	217.58
Selling Shareholders					
1.	Rosewood Investments	21,825,492	147.21	N.A.	N.A.
2.	India Business Excellence Fund - III	15,160,906	147.21	N.A.	N.A.

As certified by M/s. A B M S & Associates, Chartered Accountants by way of their certificate dated August 18, 2026.

^{*}Also participating as the Promoter Selling Shareholder.

Weighted average cost of acquisition of all equity shares transacted in the one year, 18 months and three years preceding the date of the Red Herring Prospectus:

Period	Weighted average cost of acquisition per equity share (in ₹) [*]	Cap Price is ‘x’ times the weighted average cost of acquisition [*]	Range of acquisition price per equity share: lowest price – highest price (in ₹) [^]
Last one year preceding the date of the Red Herring Prospectus	201.04	To be updated upon finalization of the Price Band	0-988.00
Last 18 months preceding the date of the Red Herring Prospectus	196.47	To be updated upon finalization of the Price Band	0-988.00
Last three years preceding the date of the Red Herring Prospectus	196.47	To be updated upon finalization of the Price Band	0-988.00

^{*}As certified by M/s. A B M S & Associates, Chartered Accountants by way of their certificate dated August 18, 2026.

[^]To be updated upon finalisation of the Price Band, in the Prospectus.

^{*}Adjusted for sub-division of equity shares

For further details, see “Capital Structure” beginning on page 106 of the Red Herring Prospectus.

10. Board of Directors and Key Managerial Personnel

The names and designations of members of the Board of Directors and Key Managerial Personnel are set forth below:

S. No.	Name	Designation
Board of Directors		
1.	Anil Satwani	Chairman and Managing Director
2.	Rohit Mantri*	Nominee Director
3.	Dhananjay Mungale [#]	Nominee Director
4.	Sunita Kishnani	Non-Executive Independent Director
5.	Pratik Patel	Non-Executive Independent Director
6.	Pramod Kasat	Non-Executive Independent Director
Key Managerial Personnel[^]		
1.	Raghavender Ramachandran	Chief Financial Officer
2.	Salil Jain	Company Secretary and Compliance Officer

*Rohit Mantri is nominated on our Board by India Business Excellence Fund – III, pursuant to the Investment Agreement.

[#]Dhananjay Mungale is nominated on our Board by Rosewood Investments, pursuant to the Investment Agreement.

[^]In addition to Anil Satwani.

For further details, see “Our Management” beginning on page 276 of the Red Herring Prospectus.

11. Auditor Qualifications

For details of qualifications which have been given effect to in the consolidated financial statements, please see “Risk Factors – 18. Our statutory auditors examination report on the Restated Consolidated Summary Statements discloses certain modifications included in their report on the consolidated financial statements as at and for the years ended March 31, 2026, March 31, 2025 and March 31, 2024”, “Restated Consolidated Summary Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Auditor Qualifications, Reservations, Adverse Remarks” on pages 42, 309 and 399, respectively.

12. Summary table of outstanding litigations

A summary of outstanding litigation proceedings involving our Company, Directors, Promoters and Subsidiaries as on the date of the Red Herring Prospectus, in accordance with the SEBI ICDR Regulations and the Materiality Policy, is provided below:

Name of Entity	Criminal proceedings	Tax proceedings	Statutory or regulatory proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoter	Material civil litigation [#]	Aggregate amount involved (in ₹ million) [*]
Company						
By the Company	1	Nil	N.A.	N.A.	Nil	Nil
Against the Company	Nil	6	Nil	N.A.	1	1,507.92
Directors (excluding Promoters)						
By the Directors	1	Nil	N.A.	N.A.	Nil	Nil
Against the Directors	2	11	Nil	N.A.	Nil	4.12
Subsidiaries						
By the Subsidiaries	Nil	Nil	N.A.	N.A.	1	Nil
Against the Subsidiaries	Nil	1	Nil	N.A.	Nil	3.67
Promoters						
By the Promoters	Nil	Nil	N.A.	N.A.	Nil	Nil
Against the Promoters	1	1	Nil	Nil	1	Nil

[#] Determined in accordance with the Materiality Policy.

^{*} To the extent ascertainable and quantifiable.

A summary of outstanding criminal proceedings and statutory or regulatory proceedings, as on the date of the Red Herring Prospectus, involving our Key Managerial Personnel and Senior Management, as disclosed in “Outstanding Litigation and Other Material Developments” in terms of the SEBI ICDR Regulations, is provided below:

Name of Entity	Criminal proceedings	Statutory or regulatory proceedings	Aggregate amount involved [*] (in ₹ million)
Key Managerial Personnel[#]			
By the Key Managerial Personnel	Nil	N.A.	Nil
Against the Key Managerial Personnel	Nil	Nil	Nil
Senior Management[@]			
By the Senior Management	Nil	N.A.	Nil
Against the Senior Management	Nil	Nil	Nil

^{*} To the extent quantifiable.

[#]Excluding Promoters who are Key Managerial Personnel, as applicable.

[@]Excluding Promoters who are members of the Senior Management, as applicable.

Further, as of the date of the Red Herring Prospectus, our Company does not have any group companies and accordingly, there are no pending litigation proceedings involving group companies which will have a material impact on our Company.

For further details of the outstanding litigation proceedings, see “Outstanding Litigation and Material Developments” beginning on page 406 of the Red Herring Prospectus.

The Equity Shares have not been recommended by any U.S. federal or state securities commission or regulatory authority. The Equity Shares offered in the Offer have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside of the United States, in offshore transactions as defined in and in reliance on Regulation S under the U.S. Securities Act (“Regulation S”) and the applicable laws of the jurisdiction where those offers and sales are made.

TIMING FOR SUBMISSION OF BID CUM APPLICATION FORMS/REVISIONS FORMS

Bids and any revision in Bids shall be accepted only between 10.00 a.m. and 5.00 p.m. (Indian Standard Time) during the Bid/ Offer Period (except the Bid/ Offer Closing Date) at the bidding centres mentioned in the Bid cum Application Forms, to the SCSBs at the Designated SCSB Branches (a list of such branches is available at the website of the SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35>) or with Designated Intermediaries. On the Bid/ Offer Closing Date, the Bids and any revision in the Bids shall be accepted only between 10.00 a.m. and 5.00 p.m. IST.

DETAILS OF BIDDING CENTRES

JM FINANCIAL SERVICES LIMITED

MUMBAI: Mr. Sona Verghese/Tejas Agrawal/Ms Armin Irani JM Financial Services Ltd, 2, 3, 4 Kamanwala Chambers, Ground Floor, Sir P M Road, Fort, Mumbai 400 001 Ph: 022-2266 5577 - 80, 6136 3400 Mr Ashit Vora/Mr. Praveen Manchekar JM Financial Services Ltd, 502, 5th Floor, Kingston, Tejpal Road, Near Railway Crossing, Vile Parle (East), Mumbai 400 057 Ph: 022-26636731-34, 26135202-03 Ms Jyotsna Solanki/Mr. Bipin Chauhan JM Financial Services Ltd, 1st Floor, 101, 1st Floor, Abhilasha II CHSL, Punjabi Lane, Off Chandavarkar Road, Borivali West, Mumbai -400092 Ph: 22 29686703 | 22 29686700 Mr. Sunil Gujar JM Financial Services Ltd, 328, 3 rd Floor, Vardhman Market, Sector 17, Above DCB, Vashi, Navi Mumbai Ph: 6632 9200/ 03/ 04/ 27896024-26 Mr. Swapnil JM Financial Services Ltd, Atlantic Commercial Tower, 211, 2nd Floor, RB Mehta Marg, Near Patel Chowk & Jain Mandir, Ghatkopar (East), Mumbai – 400 077 Ph: 022 – 25013607 Mr. Nayan Parikh/Ms. Jyoti Sharma JM Financial Services Ltd, Abhishek Commercial Complex, Office No. 8, 1st Floor, Above Dena Bank, Next to Aditi Hotel, Plot No. 104, S V Road, Malad West, Mumbai-400064 Ph: 022- 288 22 831 / 32 /34 Ms. Prajakta Bhawe JM Financial Services, Corner Stone, 2nd Floor, Office No. 209, Plot No. CTS N0-75/B, Tika Nagar 18, Hari Niwas Circle, Thane West-400602 Sachin M Tamhankar/ Shrikant Sathe Almondz Global Securities, C/o. 9, Crescent Chambers, 2nd Floor, 56, Tamirand Lane, Fort, Mumbai-400001 Ph: 022-22618137 Mr. Rajesh Tadani Centrum Broking Ltd, Centrum House, CST Road, Vidyanagri Marg, Kalina, Santacruz East, Mumbai-400098 Ph: 42159000 Dinesh Waghela Dinesh Waghela, LKP Securities, 207, Veena Chambers, 21 Dalal Street, Fort, Mumbai-400001. Ph: 022-22660171 Ph: 022-22660171 Mr. Prakash Boricha/Mr. Madhuri Tawde Nuvama Wealth and Investment Limited (Edelweiss Broking Limited), 104, P J towers, BSE Bldg, Fort, Mumbai -01 Ph: 022-67494580 Unit 21/ B, 2nd floor, Vasudev Chambers, Old Nagardas Cross Road, Andheri East, Mumbai-400069 Kamal Padia Eureka Stock & Share Broking Services Ltd, Raheja Chambers, R. No. 909, 9th Floor, Nariman Point Mumbai - 400 021 Ph: (022) 3258 3020 HDFC Securities Limited, I Think Techno Campus Building-B, "Alpha", Office Floor 8, Opp. Crompton Greaves, Near Kanjurmarg Station Kanjurmarg(East), Mumbai 400 042 India Ph: 022-30753440 Mitesh Shah/Vivek Anerao/Mr. Rajat Rawal ICICI Securities Limited, ICICI Venture House, 2nd Floor, Institution Operations, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400025, Ph: 022-6807 7463 Abhijit Prabhu IDBI Capital Markets & Securities, 5th Floor, IDBI Tower, Cuffe Parade, Colaba, Mumbai-400005 Ph: 9619817448/022-22171946 Kotak Securities Limited, 32, Gr Flr, Raja Bahadur Compound, Opp Bank of Maharashtra, Fort, T: 22655084; Archana Dedhia SBICAP Securities, Marathon Future, A&B Wing, 2nd Floor, Lower Parel Mumbai-400013 Ph: 022-42273446 Pankaj Patel/Yatish Sharekhan Ltd, 10th Floor, Beta building, Lodha iThink Techno Campus, Off; JVL R, Opp. Kanjurmarg Railway Station, Kanjurmarg (E), Mumbai-400042 Ph: 022-67502000 SMC Global, 258, Perin Nariman Street First Floor Fort mumbai -400001 Ph no 9930055430 Asit C Mehta Investment Intermediated Ltd, 67, Poddar Chambers, S A Brelvi Road, Fort, Mumbai-400001 Ph: 61325959 Mr. Shrikrishna Haryan YES Securities (India) Limited, AFL House, 4th Floor, Lok Bharati Complex, Marol-Maroshi Road, Andheri (E), Mumbai -400059 Tel: +91 (22) 3347 7017 |Mob: (+91) 95940 83673 Mr. Nilesh Shinde Prabhudas Lilladher Pvt Ltd, Sadhana House, 3 rd Floor, 570, P. B. Marg, Behind Mahindra Tower, Worli, Mumbai-400018 Tel: 022-66322222/91 Shekhar Margaje Anand Rath, A - Wing, 901, 9th Floor, Express Zone, Western Express Highway, Opp. Oberoi Mall, Malad(East), Mumbai - 400 097 Ph: 9869323656 Sunil Singh Anand Rath, Shop no. 5, Arihant Darshan, 90 Feet Road, Next to IDBI BANK. Bhayandar (W) – 401101 Ph: 9867934960 Avinash Singh Anand Rath, Shop No. 10, Grd Flr, Chandan Mansion, Opp. Portuguese Church, Gokhale Road, Dadar (W), Mumbai – 400028 Ph: 9819918988 Nilesh Pandya Anand Rath, Grd Flr, Shop No. 3&4, Raghukul Bldg, Tata Lane, Near Kasturi Plaza, Ramnagar, Dombivali (E) Ph: 9892313432 Ballabh Kothari Anand Rath, Shop No. 55, Grd Flr, Bhatia Niwas, Bhuleshwar, 466, Chira Bazar, J. S. S Road, Mumbai 400002 Ph: 9324843611 DEEPAK K VYAS Anand Rath, SHOP 11 GROUND FLR, THACKER TOWER, PLOT 86, SECTOR 17, VASHI, NAVI MUMBAI-400703 Ph: 9833489090 Mrs. Vinita Shenoy IIFL Capital Services Ltd (Formerly known as IIFL Securities Ltd), 1A, Building No 105, Opp. Bharat House, Mumbai Samachar Marg, Fort Mumbai. Pin: 400001 9167997482/ 9167997481 Ms. Saili Patil IIFL Capital Services Ltd (Formerly known as IIFL Securities Ltd), 201, 2nd Flr, Cabin No: 5, Parasmani Shopping Centre, Parasmani Complex, Nr Dadar Rlwy Stn, 95 Naigaum Cross Rd, MMGS Marg, Dadar. Pin 400014 7798307393 Mr. Bijendra Singh IIFL Capital Services Ltd (Formerly known as IIFL Securities Ltd), 6th Floor, Ackruti Centre Point, Central Road, Marol MIDC, Andheri East, Mumbai. Pin 9004930729 Mr. Umesh Yeram IIFL Capital Services Ltd (Formerly known as IIFL Securities Ltd), Shree Manek Nagar CHS, Office No. 6, Punjabi Lane, Borivali West, Mumbai, Maharashtra; (Opp New India Bank). Pin 400092 9850207105 Mr. Sandeep Bugade IIFL Capital Services Ltd (Formerly known as IIFL Securities Ltd), Ground Floor, Hubtown Solaris, N. S. Phadke Marg, Vijay Nagar, Opp Teli Galli, Andheri (East), Mumbai 400 069. Pin 400069 9969750852 Ms Amee Shah IIFL Capital Services Ltd (Formerly known as IIFL Securities Ltd), Shop no 2, Surya darshan apt, J s Road, Near Ganjawala petrol pump, Borivali west, Mumbai – 400092 99871 63707 Atul Padwal IIFL Capital Services Ltd (Formerly known as IIFL Securities Ltd), Shop No. 28 Ground Floor, Platinum mall, Near BMc Office, Jawahar road, Ghatkopar East 8268883091 Harsh Thakkar IIFL Capital Services

DETAILS OF BIDDING CENTRES

Ltd (Formerly known as IIFL Securities Ltd), Shop no. 3 ground floor, building name manav mandir, tika no. 16, ram maruti riad, panchpakhadi, thane west 400602. Pin 400602 99206 31143 Mahajan KJMC Capital Market Services, 168, 16Th Floor, Atlanta, 209, Nariman Point, Mumbai-400021 Ph: 22885201 **NEW DELHI:** Mr. Umesh Yadav/Mr. Ashishkumar Jhigran JM Financial Services Ltd, 5 G&H, 5th Floor, Hansalaya Building, 15, Barakhamba Road, New Delhi -110 001 Phone (011) 49537800 Manoj Arora/Manish Chopra Almondz Global Securities, 2nd Floor, 3-Scindia House, Janepath, New Delhi-110001 Ph: 011-41514666-69 Kotak Securities Limited, Unit number 601 & 608, 6th Floor, World Trade Tower Building, Tower B, Plot number C1, Sector 16, Noida, (New Delhi) - 201301. Tel: 0120-6760435/0120-4869326; Religare Securities Ltd, 2nd Floor, Rajlok Building, 24, Nehru Place, New Delhi Ph: 11 46272400 Religare Securities Ltd, Ground Floor, Property No. 1, DLF Industrial Area, Moti Nagar, New Delhi Ph: 918800191497 Jeethesh Kumar RR Equity Brokers, 47, M M Road, Rani-Jhansi Marg, Jhandewalan, New Delhi-110055 Ph: 011-22636362-63 SMC Global, 17, Netaji Subhash Marg, Daryaganj, New Delhi-110 002 Ph no 9910644949, 8595851823 Jyoti Dodeja Anand Rathi, 2nd Floor, Unit No. 6, DDA Building No. 11, Vardhman Trade Centre, Nehru Place, New Delhi- 110 019 Ph: 9313133170/81301 07700 Mr. Puneet Gupta Globe Capital Markets, 609, Ansal Building, 16 KG Marg, Connaught Place, New Delhi 110001 Axis Capital Ltd, 2nd Floor, Level 3B (4th Floor), DLF Centre, Ansad Marg, Connaught Place, New Delhi, Pin: 110001, Ph: 011 - 61289088, Mr. Manish Chopra IIFL Capital Services Ltd (Formerly known as IIFL Securities Ltd), 510-514, 5th Floor, Ashoka Estate Bldg - 24, Barakhamba Road, Connaught Place 9310527000/ 9871047900

AVENDUS CAPITAL PRIVATE LIMITED

MUMBAI: 901, Platina, 9th Floor, Plot No. C-59, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 India

MOTILAL OSWAL FINANCIAL SERVICES LIMITED

MUMBAI:- Motilal Oswal Financial Services Limited - "4TH Floor, Interface 11, Mind Space New Link Road, Malad West Mumbai – 400064. “, Tel :-MUMBAI:- Centrum Broking Limited - Level 3, Centrum House, CST Road, Vidyanagari Marg, Kalina, Santacruz (E), Mumbai 400098, ., Tel :-MUMBAI:-YES Securities (India) Limited - AFL House, 4th Floor, Lok Bharti Complex, Marol Maroshi Road Andheri (E) Mumbai – 400059., Tel :-MUMBAI:-Prabhudas Lilladher Pvt Limited - 3rd Floor, Sadhana House, 570, P.B. Marg, Worli, Mumbai - 400018., Tel :-MUMBAI:-Asit C. Mehta Investment Intermediates Limited - Pantomath Nucleus House,Saki-Vihar Road, Andheri East,Mumbai-400072 Maharashtra., Tel :-MUMBAI:-Anand Rathi Share & Stock Brokers Limited - Anand Rathi, A - Wing, 901, 9th Floor, Express Zone, Western Express Highway, Opp. Oberoi Mall, Malad(East), Mumbai - 400 097., Tel :-MUMBAI:-SBICAP Securities Limited, - Marathon Futurex, 12th floor, A&B wing, Mafatlala Mill Compound, N. M. Joshi Marg, Lower Parel, Mumbai : 400013., Tel :-MUMBAI:-Almondz Global Securities Limited - 2nd Floor, 27 - Sanghavi Chambers, Opp. Janmabhoomi Bhavan, Janmabhoomi Marg, Fort, Mumbai 400 001., Tel :-MUMBAI:-Finwizard Technology Private Limited - Office No.1002, A wing, 10th Floor, Kanakia Wall Street, Hanuman Nagar, Andheri Kurla Road, Chakala, Andheri (East), Mumbai 400093., Tel :-MUMBAI:-KJMC Capital Market Services Limited - 168, 16th Floor, Atlanta Building, Nariman Point, Mumbai – 400 021., Tel :-MUMBAI:-LKP Securities Limited - 207, Veena Chambers 21 Dalal Street Fort Mumbai 400 001., Tel :-MUMBAI:-SMC Global Securities Limited - 258, Perin Nariman Street First Floor Fort mumbai -400001 ., Tel :-MUMBAI:-TradeBulls Securites (P) Limited. - Manoj Villa, 1 st Flr, Above Dena Bank, Near Mc Donald's, Dr. Joshi Road, Vile Parle (W) , Mumbai-400056 ., Tel :-MUMBAI:-HDFC SECURITIES Limited - I Think Techno Campus, Building, B, Alpha,Office Floor 8, Near Kanjurmarg Station,Kanjurmarg (East), Mumbai -400 042. ., Tel :-MUMBAI:-Nuvama Wealth and Investment Limited - 104, P J towers, BSE Bldg, Fort, Mumbai -01., Tel :-MUMBAI:-RR Equity Brokers Pvt. Limited. - 82/1, Apollo House, Ground Floor, Opposite Jammu & Kashmir Bank, Mumbai Samachar Marg, Mumbai 400023, MAHARASHTRA., Tel :-MUMBAI:-ICICI SECURITIES Limited - ICICI Securities Limited, ICICI Venture House, 2nd Floor, Institution Operations,Appasaheb Marathe Marg,Prabhadevi, Mumbai - 400025, India., Tel :-MUMBAI:-IIFL Capital Services Limited - 1A/105, Ground Floor , Opp Bharat House , Near Kalaghoda Dive , Mumbai Samachar Marg Fort Mumbai 400001., Tel :-MUMBAI:-IIFL Capital Services Limited - 201; Cabin No 6 ; Ratnamani Tower 2nd Floor , Parasmani Complex ; 95, M.M.G.S Marg, Near Dadar Station;Dadar (East); Mumbai – 400014., Tel :-MUMBAI:-IIFL Capital Services Limited - 6th Floor, Ackruti Centre Point, Central Road,Marol MIDC, Andheri East, Mumbai ., Tel :-MUMBAI:-IIFL Capital Services Limited - 311-Jalaram business Center 3rd flr Ganjawalla Lane chamunda circle Above Axis Bank Borivali west, Mumbai 400 092., Tel :-MUMBAI:-IIFL Capital Services Limited - IIFL Securities Ltd ,Ground Floor,Huhtown Solaris,N. S. Phadke Marg, Vijay Nagar,Opp Teli Galli, Andheri (East),Mumbai 400 069., Tel :-MUMBAI:-IIFL Capital Services Limited - Shop No 2, Ground Floor, Surya Darshan Apt,Pai Nagar, Near Ganjawala Petrol Pump,Borivali West, Mumbai - 400092., Tel :-MUMBAI:-DALAL & BROACHA STOCK BROKING PVT Limited - “MUTUAL FUND DIVISION514 MAKER CHAMBER V221, NARIMAN POINT,MUMBAI - 400 021”., Tel :-MUMBAI:-Upstox Securities Private Limited - Sunshine Tower, 30th Floor, Senapati Bapat Marg, Dadar (W), Mumbai - 400 013., Tel :-MUMBAI:-Kantilal Chhaganlal Securities Pvt.Limited - 601/ 602, INIZIO, Cardinal Gracious Road, Opp. P&G Plaza, Chakala, Andheri East, Mumbai – 400 099., Tel :-MUMBAI:-Sharekhan Limited - Gigaplex Building No. 09, 10th Floor,Raheja Mindspace 2, Airoli Knowledge Park,Airoli – Navi Mumbai 400708., Tel :-MUMBAI:-Arihant Capital Markets Limited - “1011, Solitaire Corporate Park, Building No. 10, 1st Floor, Guru Hargovindji Road, Chakala, Andheri (East), Mumbai - 400093, India”., Tel :-MUMBAI:-Keynote Capitals Ltd - 9th Floor, The Ruby, Senapati Bapat Marg, Dadar West, Mumbai, Maharashtra, 400028, India., Tel :-MUMBAI:-5paisa Capital Limited - IIFL House, Sun Infotech Park, Road No.16V, Plot No. B-23, MIDC, Wagle Estate Rd, Industrial Area, Thane, Maharashtra 400604., Tel :-MUMBAI:-Anand Rathi Share & Stock

DETAILS OF BIDDING CENTRES

Brokers Limited - Anand Rath, Shop No. 1 , Vishal CHSL, 1st floor Opp Maxus Banquet Hall , Temba Hospital Road, Bhayander west , Thane 401101., Tel :-MUMBAI :-Anand Rath Share & Stock Brokers Limited - Anand Rath, Unit No. 37-A, First Floor, King's Krest, Bhawani Shankar Road, Dadar (W), Mumbai 400028., Tel :-MUMBAI :-Anand Rath Share & Stock Brokers Limited - Anand Rath, Grd Flr, Shop No. 3&4, Raghukul Bldg, Tata Lane, Behind Kasturi Plaza, Ramnagar, Dombivali €, Tel :-MUMBAI :-Anand Rath Share & Stock Brokers Limited - Anand Rath, 466, Chira Bazar, J.S.S Road, Opp Dr Vigas Street, Mumbai 400002., Tel :-MUMBAI :-Anand Rath Share & Stock Brokers Limited - F 101/102 ,FIRST FLOOR,INTERNATIONAL INFOTECH PARK TOWER 7, VASHI RAILWAY STATION, COMMERCIAL COMPLEX, SECTOR 30 A ,VASHI, NAVI MUMBAI - 400705., Tel :-MUMBAI :-Kotak Securities Limited - 32, Gr Flr., Raja Bahadur Compound, Opp Bank of Maharashtra, Fort 400001., Tel :-MUMBAI. **NEW DELHI**:-Axis Capital Limited - The Executive Centre Level 3B (4th Floor), DLF Centre, Sansad Marg, Connaught Place, New Delhi.- 110001., Tel :-NEW DELHI:-Anand Rath Share & Stock Brokers Limited - Anand Rath, 2nd Floor, Unit No. 6, DDA Building No. 11, Vardhman Trade Centre, Nehru Place, New Delhi- 110 019., Tel :-NEW DELHI:-Almondz Global Securities Limited - "F - 33/3, Okhla Industrial Area, Phase - II, New Delhi - 110020 "., Tel :- NEW DELHI:-SMC Global Securities Limited - 17 , Netaji Subhash Marg, Daryaganj, New Delhi-110 002., Tel :-NEW DELHI:-SS Corporate Securities Limited - NDM-2, Block - D, 3rd Floor, Netaji Subhash Place, Pitampura, Delhi-110034., Tel :-NEW DELHI:-RR Equity Brokers Pvt. Limited. - 412-422, Indraprakash Building, 21, Barakhamba Road, New Delhi – 110001., Tel :-NEW DELHI:-IIFL Capital Services Limited - 510-514, 5th Floor, Ashoka Estate Building, Barakhamba Road, New Delhi - 110001.,Tel :-NEW DELHI:-Alankit Imaginations Limited - Alankit Heights|1E/13 Jhandewalan Extension|New Delhi - 110055.,Tel :-New Delhi:-Kotak Securities Limited - Unit number 601 & 608, 6th Floor, World Trade Tower Building, Tower B, Plot number C1, Sector 16, Noida, (New Delhi) - 201301.

NOMURA FINANCIAL ADVISORY AND SECURITIES (INDIA) PRIVATE LIMITED

MUMBAI: Ceejay House, Level 11, Plot F, Shiv Sagar Estate, Dr. Annie Besant Marg, Worli, Mumbai 400 018, Maharashtra, India

THIS SPACE IS INTENTIONALLY LEFT BLANK

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID REVISION FORM

I/We (on behalf of joint Bidders, if any) confirm that the Acknowledgement Slip for my/our Bids is enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in this Bid cum Application Form submitted earlier by me/us. I/We (on behalf of joint Bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my/our existing Bids as appearing on the electronic book building system do not tally with the details given in this Bid Revision Form.

INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM

- Name of sole/first Bidder should be exactly the same as it appears in the depository records. In case of joint Bids, the Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The Bid means an "indication to make an offer" and not "an offer".
- Please ensure that the Bid options provided are in the same order as that provided in the Bid cum Application Form submitted earlier.
- In case there is no change in the particular Bid option, please write "NO CHANGE". In case you want to cancel the Bid option, please write "CANCELLED".
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total Bid Amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your bank has notified an SCSB Branch in the city where the Bid cum Application Form is being submitted.
- Revision of Bids in case of Revision of Price Band:** In case of an upward revision in the Price Band, Retail Individual Bidders who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount) plus additional payment does not exceed ₹200,000 (if the Bidder wants to continue to Bid at Cut-off Price), with the SCSBs' Members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds ₹200,000, the Bid will be considered for allocation under the Non-Institutional Portion in terms of the RHP or the Preliminary Offering Memorandum as applicable. If, however, the Bidder does not either revise the Bid or make additional payment and the Offer Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. In case of a downward revision in the Price Band, announced as above, UPI is mechanism, and RII will be the bidders who have bid at Cut-off Price, could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
- Only the Sole Bidder/First Bidder is required to sign the Bid cum Application Form/Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of Sole Bidder and ASBA bank account or UPI ID linked with the bank account of first Bidder in case of joint Bidder, in the application form. If the first Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c are liable to be rejected.
 - QIBs and Non-Institutional Bidders with bids more than ₹500,000 cannot use UPI mechanism to apply. UPI Bidders applying up to ₹500,000 can apply through UPI mode as per NPCI vide circular reference no. NPCI/UI/OC No. 127/2021-22 dated December 09, 2021 read with SEBI Master Circular no. HO/49/14/4/2026-CFD-PD/21/4518/2026 dated February 09, 2026.
 - For Retail Individual Bidders (RIIs) and Non-Institutional Bidders with Application size up to ₹500,000 ("UPI Bidders") bidding through the UPI Mechanism:**
 - Please ensure that your bank is offering UPI facility for public Offers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/otherOtherAction.do?doRecognisedPr=y&scintmlid=40>) and (<https://www.sebi.gov.in/sebiweb/otherOtherAction.do?doRecognisedPr=y&scintmlid=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
 - UPI Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on page 451 of the RHP.
- Other Instructions:** a. Revision to Bids must be made only in the prescribed Revision Form, as applicable; b. Revision Form must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the members of the Syndicate/ SCSBs/Registered Brokers/RTA/CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Forms; c. Ensure that Acknowledgement Slip for your Bid and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to Offer instruction to block the revised amount in excess of their original blocked amount based on the cap of the revised Price Band upon an upward revision of their Bid.
- Revisions in the Bid, the Bidders/Applicants will have to use the services of the same Designated Intermediary through which such Bidder/Applicant had placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Revision Form and the Bid(s) must be made only in such Revision Form or copies thereof.

OFFER STRUCTURE

Particulars	QIBs ⁽¹⁾	Non-Institutional Bidders	Retail Individual Bidders	Eligible Employees
Number of Equity Shares available for Allotment / allocation^(a)	Not more than [●] Equity Shares of face value of ₹2 each	Not less than [●] Equity Shares of face value of ₹2 each available for allocation or Net Offer less allocation to QIB Bidders and Retail Individual Bidders.	Not less than [●] Equity Shares of face value of ₹2 each available for allocation or Net Offer less allocation to QIB Bidders and Non-Institutional Bidders	Up to [●] Equity Shares of face value of ₹2 each, aggregating up to ₹30.00 million
Percentage of Offer Size available for Allotment / allocation	Not more than 50% of the Net Offer size shall be available for allocation to QIB Bidders. However, 5% of the Net QIB Portion will be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining balance Net QIB Portion. The unsubscribed portion in the Mutual Fund Portion will be available for allocation to other QIBs in the Net QIB Portion	Not less than 15% of the Net Offer, or the Net Offer less allocation to QIB Bidders and Retail Individual Bidders, subject to the following: - one-third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than ₹20.20 million and up to ₹1.00 million, and - two-third of the Non-Institutional Portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories may be allocated to Bidders in the other sub-category of Non-Institutional Bidders.	Not less than 35% of the Net Offer, or the Net Offer less allocation to QIB Bidders and Non-Institutional Bidders	The Employee Reservation Portion constitutes up to [●] % of the post-Offer Equity Share capital of our Company
Basis of Allotment / allocation if respective category is oversubscribed^(b)	Proportionate as follows (excluding the Anchor Investor Portion): - Up to [●] Equity Shares of face value of ₹2 each shall be available for allocation on a proportionate basis to Mutual Funds only; and - Remaining [●] Equity Shares of face value of ₹2 each shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above Up to 60% of the QIB portion (of up to [●] Equity Shares of face value of ₹2 each) may be allocated on a discretionary basis to Anchor Investors. 40% of the Anchor Investor Portion shall be available for allocation as follows, (i) 33.33% shall be available for allocation to domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the Anchor Investor Allotment Price. In the event of under-subscription in (ii) above, the allocation may be made to domestic Mutual Funds.	The [●] Equity Shares of face value of ₹2 each available for allocation to Non-Institutional Bidders under the Non-Institutional Portion, shall be subject to the following: - one-third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than ₹20.20 million and up to ₹1.00 million, and - two-third of the Non-Institutional Portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories may be allocated to Bidders in the other sub-category of Non-Institutional Bidders. The Allotment to each Non-Institutional Bidder shall not be less than the minimum application size, subject to the availability of Equity Shares in the Non-Institutional Portion, and the remaining Equity Shares, if any, shall be allotted on a proportionate basis. For details, see "Offer Procedure" on page 451 of the RHP.	The Allotment to each Retail Individual Bidder shall not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining available Equity Shares if any, shall be allotted on a proportionate basis. For details, see "Offer Procedure" on page 451 of the RHP.	Proportionate, unless the Employee Reservation Portion is undersubscribed, the value of allocation to an Eligible Employee shall not exceed ₹20 million (net of Employee Discount, if any). In the event of undersubscription in the Employee Reservation Portion, the unsubscribed portion may be allocated, on a proportionate basis, to Eligible Employees for a value exceeding ₹20 million (net of Employee Discount, if any) up to ₹50.50 million (net of Employee Discount, if any) each. ⁴
Minimum Bid	Such number of Equity Shares in multiples of [●] Equity Shares of face value of ₹2 each, that the Bid Amount exceeds ₹20 million	Such number of Equity Shares in multiples of [●] Equity Shares of face value of ₹2 each that the Bid Amount exceeds ₹20 million	[●] Equity Shares of face value of ₹2 each	[●] Equity Shares of face value of ₹2 each
Maximum Bid	Such number of Equity Shares in multiples of [●] Equity Shares of face value of ₹2 each not exceeding the size of the Net Offer (excluding the Anchor Investor portion), subject to applicable limits under applicable law	Such number of Equity Shares in multiples of [●] Equity Shares of face value of ₹2 each not exceeding the size of the Net Offer (excluding the QIB Portion), subject to limits prescribed under applicable law	Such number of Equity Shares in multiples of [●] Equity Shares of face value of ₹2 each so that the Bid Amount does not exceed ₹20 million	Such number of Equity Shares and in multiples of [●] Equity Shares of face value of ₹2 each so that the maximum Bid Amount by each Eligible Employee in this portion does not exceed ₹50 million (net of Employee Discount, if any) ⁴
Bid Lot	[●] Equity Shares of face value of ₹2 each and in multiples of [●] Equity Shares of face value of ₹2 each thereafter			
Mode of allotment^(c)	Compulsorily in dematerialised form			
Allotment Lot	A minimum of [●] Equity Shares of face value of ₹2 each and in multiples of [●] Equity Share thereafter QIBs, RIIs & Eligible Employees. For Non-Institutional Bidders allotment shall not be less than the minimum non-institutional application size.			
Trading Lot	One Equity Share of face value of ₹2 each			
Who can apply^(3b)	Public financial institutions (as specified in Section 2(72) of the Companies Act), scheduled commercial banks, Mutual Funds, Eligible FPIs other than individuals, corporate bodies and family offices, VCFs, AIFs, FVCIs registered with SEBI, multilateral and bilateral development financial institutions, state industrial development corporation, insurance companies registered with IRDAI, provident funds (subject to applicable law) with minimum corpus of ₹250 million, Pension Funds with minimum corpus of ₹250 million registered with the Pension Fund Regulatory and Development Authority established under sub-section (1) of section 3 of the Pension Fund Regulatory and Development Authority Act, 2013, National Investment Fund set up by the Government of India, the insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, and India Systemically Important Non-Banking Financial Companies.	Resident Indian individuals, Eligible NRIs, HUFs (in the name of the karta), companies, corporate bodies, scientific institutions, societies and trusts and any individuals, corporate bodies and family offices which are re-categorised as category II FPIs and registered with SEBI	Resident Indian individuals, Eligible NRIs and HUFs (in the name of the karta) applying for Equity Shares such that the Bid amount does not exceed ₹20.20 million in value	Eligible Employees such that the Bid Amount does not exceed ₹50.50 million, (net of Employee Discount, if any).
Terms of Payment	In case of Anchor Investors: Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids ⁽⁴⁾ In case of all other Bidders: Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder (other than Anchor Investors) or by the Sponsor Bank(s) through the UPI Mechanism, that is specified in the ASBA Form at the time of submission of the ASBA Form.			
Mode of Bidding⁽⁵⁾	Only through the ASBA process (except for Anchor Investors). In case of UPI Bidders, ASBA process will include the UPI mechanism.			

Assuming full subscription in the Offer.

Anchor Investors are not permitted to use the ASBA process. Further, SEBI vide the SEBI ICDR Master Circular, had mandated that ASBA applications in Public Issues shall be processed only after the application monies are blocked in the investor's bank accounts. Accordingly, Stock Exchanges shall, for all categories of investors and also for all modes through which the applications are processed, accept the ASBA applications in their electronic book building platform only with a mandatory confirmation on the application monies blocked.

Eligible Employees bidding in the Employee Reservation Portion can bid up to a Bid Amount of ₹0.50 million (net of Employee Discount, if any). However, a Bid by an Eligible Employee in the Employee Reservation Portion will be considered for allocation, in the first instance, for a Bid Amount of up to ₹0.20 million (net of Employee Discount, if any). In the event of under-subscription in the Employee Reservation Portion the unsubscribed portion will be available for allocation and Allotment, proportionately to all Eligible Employees who have Bid in excess of ₹0.20 million (net of Employee Discount, if any), subject to the maximum value of Allotment made to such Eligible Employee not exceeding ₹0.50 million (net of Employee Discount, if any). Further, an Eligible Employee Bidding in the Employee Reservation Portion can also Bid in the Net Offer and such Bids will not be treated as multiple Bids subject to applicable limits. The unsubscribed portion, if any, in the Employee Reservation Portion shall be added back to the Net Offer. In case of undersubscription in the Net Offer, spill-over to the extent of such undersubscription shall be permitted from the Employee Reservation Portion. However, undersubscription, if any, in the QIB Portion will not be allowed to be met with spill-over from other categories or a combination of categories.

⁽⁶⁾ Our Company in consultation with the BRLMs, may allocate a discount of up to [●] % on the Offer Price (equivalent of ₹[●] per Equity Share) to Eligible Employees bidding in the Employee Reservation Portion which shall be announced two Working Days prior to the Bid / Offer Opening Date.

(1) Our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations and subject to there being (i) minimum of two and maximum of 15 Anchor Investors, where the allocation under the Anchor Investor Portion is up to ₹2,500.00 million, subject to a minimum Allotment of ₹50.00 million per Anchor Investor, and (ii) in case of allocation above ₹2,500.00 million under the Anchor Investor Portion, a minimum of five Anchor Investors and a maximum of 15 Anchor Investors for allocation up to ₹2,500.00 million, and an additional 15 Anchor Investors for every additional ₹2,500.00 million or part thereof will be permitted, subject to minimum allotment of ₹50.00 million per Anchor Investor. 40% of the Anchor Investor Portion shall be reserved for (i) 33.33 per cent for domestic Mutual Funds; and (ii) 6.67 per cent for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the Anchor Investor Allotment Price. In the event of under-subscription or non-Allotment in the Anchor Investor Portion, the balance Equity Shares in the Anchor Investor Portion shall be added to the Net QIB Portion. For further details, see "Offer Procedure" on page 451 of the RHP.

(2) Subject to valid Bids being received at or above the Offer Price. The Offer is being made in terms of Rule 19(2)(b) of the SCRR read with Regulation 45 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in accordance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to QIBs. Such number of Equity Shares representing 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only. The remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to QIBs, including Mutual Funds, subject to valid Bids being received from them at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to all QIBs. Further, not less than 15% of the Offer shall be available for allocation to Non-Institutional Bidders and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. The Equity Shares available for allocation to Non-Institutional Bidders under the Non-Institutional Portion, shall be subject to the following: (i) one-third of the portion available to Non-Institutional Bidders shall be reserved for Bidders with an application size of more than ₹20.20 million and up to ₹1.00 million, and (ii) two-third of the portion available to Non-Institutional Bidders shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories may be allocated to Bidders in the other sub-category of Non-Institutional Bidders. Subject to valid Bids being received at or above the Offer Price, under-subscription, if any, in the Non-Institutional Portion or the Retail Portion would be allowed to be met with spill-over from other categories or a combination of categories at the discretion of our Company, in consultation with the BRLMs and the Designated Stock Exchange, on a proportionate basis. However, under-subscription, if any, in the QIB Portion will not be allowed to be met with spill-over from other categories or a combination of categories. For further details, please see "Terms of the Offer" on page 439 of the RHP.

(3) In the event that a Bid is submitted in joint names, the relevant Bidders should ensure that the depository account is also held in the same joint names and the names are in the same sequence in which they appear in the Bid cum Application Form. The Bid cum Application Form should contain only the name of the First Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such First Bidder would be required in the Bid cum Application Form and such First Bidder would be deemed to have signed on behalf of the joint holders. Our Company reserves the right to reject, in its absolute discretion, all or any multiple Bids in any or all categories.

(4) Anchor Investors shall pay the entire Bid Amount at the time of submission of the Anchor Investor Bid, provided that any positive difference between the Anchor Investor Allotment Price and the Offer Price, shall be payable by the Anchor Investor Pay-in Date as mentioned in the C.A.N.

(5) Bids by FPIs with certain structures as described under "Offer Procedure – Bids by FPIs" on page 458 and having same PAN may be collated and identified as a single Bid in the Bidding process. The Equity Shares Allotted and Allotted to such successful Bidders (with same PAN) may be proportionately distributed.

COMMON BID
REVISION FORM

(Please scan this QR Code to view the Red Herring Prospectus, Price Band Ad and Abridged Prospectus)

SYMBIOTEC PHARMALAB LIMITED - INITIAL PUBLIC OFFER - NR

Corporate Identity Number: U24232MP2002PLC015293; Website: www.symbiotec.com
Registered and Corporate Office: 385/2, Pigdamber, Rau, Mhow, Indore - 453 331, Madhya Pradesh, India
Contact Person: Salil Jain, Company Secretary and Compliance Officer; Telephone: +91 731 667 6405;
Email: secretarial@symbiotec.com

FOR NON-RESIDENTS INCLUDING ELIGIBLE NRIs, FPIs OR FVCI-REGISTERED MULTILATERAL AND BILATERAL DEVELOPMENT FINANCIAL INSTITUTIONS APPLYING ON A REPATRIATION BASIS



To,
The Board of Directors
SYMBIOTEC PHARMALAB LIMITED

100% BOOK BUILT OFFER
ISIN: INE899I01028
LEI: 335800C8X96Y9XFOZS81

Bid cum Application Form No.

MEMBERS OF THE SYNDICATE STAMP & CODE	SUB-SYNDICATE MEMBER'S/REGISTERED BROKER'S/SCSB'S/CDP'S / RTA'S STAMP & CODE
SUB-BROKER / SUB-AGENT STAMP & CODE	SCSB BRANCH STAMP & CODE
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.

1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER			
Mr. /Ms./M/s. _____			
Address _____			
_____ Email _____			
Tel. No. (with STD code) / Mobile _____			
2. PAN OF SOLE / FIRST BIDDER			

3. BIDDER'S DEPOSITORY ACCOUNT DETAILS ☐ NSDL ☐ CDSL			
For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID			

PLEASE CHANGE MY BID

Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised)								Price per Equity Share (₹)/ "Cut-off Price" (Price in multiples of ₹ 1/- only)											
	(In Figures)								(In Figures Only)											
	8	7	6	5	4	3	2	1	Bid Price			Retail Discount			Net Price			"Cut-off" (Please ✓ tick)		
Option 1									3	2	1	3	2	1	3	2	1	☐		
(OR) Option 2																		☐		
(OR) Option 3																		☐		

Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised)								Price per Equity Share (₹)/ "Cut-off Price" (Price in multiples of ₹ 1/- only)											
	(In Figures)								(In Figures Only)											
	8	7	6	5	4	3	2	1	Bid Price			Retail Discount			Net Price			"Cut-off" (Please ✓ tick)		
Option 1									3	2	1	3	2	1	3	2	1	☐		
(OR) Option 2																		☐		
(OR) Option 3																		☐		

6. PAYMENT DETAILS [IN CAPITAL LETTERS]																		PAYMENT OPTION : FULL PAYMENT ☒									
Amount Blocked (₹ in figures) _____																		(₹ in words) _____									
ASBA Bank A/c No. _____																											
Bank Name & Branch _____																											
Bank A/c reference number _____																											
OR UPI ID (Maximum 45 characters) _____																											

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS COMMON BID REVISION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC OFFER ("GID") AND HEREBY AGREE AND CONFIRM THE "BIDDER'S UNDERTAKING" AS GIVEN ALONG WITH THE BID CUM APPLICATION FORM. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE COMMON BID REVISION FORM GIVEN OVERLEAF.

7A. SIGNATURE OF SOLE/ FIRST BIDDER																		7B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)																		7C. MEMBERS OF THE SYNDICATE / SUB-SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchanges system)																	
Date : _____, 2026																		I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer.																																			
																		1) _____																																			
																		2) _____																																			
																		3) _____																																			

TEAR HERE

SYMBIOTEC PHARMALAB LIMITED																		Acknowledgement Slip for Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agents																		Bid cum Application Form No.																	
COMMON BID REVISION FORM - INITIAL PUBLIC OFFER - NR																																																					
DP ID / CL ID _____																		PAN of Sole / First Bidder _____																																			
Additional Amount Blocked (₹ in figures) _____																		ASBA Bank A/c No./UPI ID _____																		STAMP & SIGNATURE OF SCSB BRANCH / MEMBERS OF THE SYNDICATE / SUB-SYNDICATE MEMBER / REGISTERED BROKER / CDP / RTA / AGENTS																	
Bank Name & Branch _____																																																					
Received from Mr./Ms./M/s. _____																																																					
Telephone / Mobile _____																		Email _____																																			

TEAR HERE

SYMBIOTEC PHARMALAB LIMITED - BID REVISION FORM - INITIAL PUBLIC OFFER - NR																		Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agents																		Name of Sole / First Bidder																	
No. of Equity Shares _____																																																					
Bid Price per Equity Share (₹) _____																																																					
Additional Amount Blocked (₹ in figures) _____																																																					
ASBA Bank A/c No. /UPI ID _____																																																					
Bank Name & Branch _____																																																					
Important Note : Application made using third party UPI ID or third party ASBA Bank Account are liable to be rejected.																																																					